Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

AuraEnergy

Aura Energy Limited

Premium
Information Technology

Aura Energy is an ASX- and AIM-listed uranium developer whose investment case rests almost entirely on the Tiris Uranium Project in northern Mauritania, an 85%-owned, fully permitted, shallow free-dig calcrete-hosted uranium deposit designed to become Mauritania's first uranium mine and the country's first new mine in roughly two decades. The 2024 FEED study and September 2024 Production Target Update defined a 2 Mlb/yr U3O8 operation with US$230m development capital and a 25-year life; a revised processing flowsheet, finalised in the June 2026 quarter, now underpins a Bankable Feasibility Study targeted for September 2026 and a Final Investment Decision targeted by end-2026. The secondary asset, the 100%-owned Häggån polymetallic (vanadium–sulphate of potash–uranium) deposit in Sweden, gained strategic optionality after Sweden repealed its uranium-mining ban. Aura remains pre-revenue, equity-funded and subject to a going-concern material uncertainty pending project finance. --- ### Company's own description In its FY2025 and FY2026 annual filings Aura describes itself as an Australian-based minerals company focused on developing uranium and battery metals to support a cleaner energy future, with an explicit ambition to transition from uranium explorer to uranium producer to capitalise on growing nuclear power demand. The principal activities recorded in the FY2026 Directors' Report are the exploration and evaluation of uranium, vanadium, and gold and base metals in Mauritania and Sweden, with no significant change in the nature of those activities during the year. The company frames its two key projects as (i) Tiris, a fully permitted near-term development asset with a potentially long mine life, and (ii) Häggån, a globally significant vanadium, sulphate of potash and uranium deposit offering long-term value. ### Independent characterisation Analytically, Aura is a single-asset development company with a long-dated option attached. Tiris is the value driver: it accounts for A$45.0m of A$73.2m consolidated assets at 30 June 2026 (Uranium segment, FY2026 Annual Report) and essentially all of the near-term catalyst path (BFS, pilot plant, offtake, financing, FID). Häggån (A$12.3m of segment assets) is a permitting and policy option whose value is contingent on Swedish legislation regarding alum-shale extraction. A residual gold and base-metals interest at Tasiast South (Mauritania) has been fully impaired and is in litigation. ### Business model and revenue model | Dimension | Current state (FY2026) | Planned state (post-FID) | |---|---|---| | Revenue | Nil from ordinary activities; only interest income (A$0.30m FY2026) | Sale of uranium oxide concentrate (UOC / U3O8) | | Product vs service mix | Not applicable | 100% product (commodity) | | Subscription / licensing | None | None | | Pricing mechanism | Not applicable | Mix of long-term contracts (fixed/base-escalated and market-related) and spot sales, per disclosed offtake framework | | Contracted offtake | Curzon Uranium offtake (restructured August 2024); long-term agreement with a major US nuclear utility (August 2025, approx. 10% of projected 2028–2031 output); master spot sales agreement with a global uranium trading group (August 2025) | Additional long-term contracting expected alongside financing; a June 2026 MOU with an international nuclear utility contemplates offtake | ### Value-chain position Aura sits at the very top of the nuclear fuel cycle: mining and milling to produce U3O8 concentrate. Downstream steps (conversion to UF6, enrichment, fuel fabrication, reactor operation) are performed by third parties such as converters, enrichers and utilities. Aura will be a price-taker in the U3O8 market, with its margin determined by realised price versus all-in sustaining cost. ### Customer types and end-markets Prospective customers are nuclear utilities (US, European and Asian), uranium traders and intermediaries, and potentially state-linked fuel buyers. The end-market is global civil nuclear power generation, with secondary exposure in Sweden to vanadium (steel alloying, vanadium redox flow batteries) and sulphate of potash (specialty fertiliser) should Häggån proceed.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2005
Fremantle, Australia

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Audalia

Audalia Resources Limited

Premium
Information Technology

Audalia Resources is a Perth-based, single-asset junior. It owns 100% of the Medcalf vanadium-titanium-iron project in the Lake Johnston region of Western Australia, about 470 km east-southeast of Perth. The company dropped an early, capital-heavy hydrometallurgical plan to extract vanadium pentoxide and titanium dioxide. It has rebased Medcalf as a low-complexity direct-shipping-ore (DSO) operation. The plan is to crush and screen weathered pyroxenite into High Titanium Lump Ore (HTLO) and High Titanium Fine Ore (HTFO) and sell them mainly to Chinese steelmakers, who use them to protect blast-furnace hearth refractories. The project has primary state environmental approval (Ministerial Statement 1228, 4 July 2024). In January 2026 it published a maiden Probable Ore Reserve of 11.77 Mt at 11.0% TiO2. A pre-feasibility study shows NPV10 of A$141M–227M against pre-production capex of A$31M–121M. Against that, the balance sheet is fragile, with about A$0.7M cash, about A$6M of director and private loans plus more than A$4M of accrued interest, and a going-concern emphasis of matter. Secondary mining approvals, offtake and development funding are all still outstanding. --- ### Company's own description In its statutory reports, Audalia describes its principal continuing activity as mineral exploration and evaluation. It reports a single operating segment, the Medcalf Project in Western Australia (H1 FY2026 Interim Report, Note 9). Its market description, carried by data vendors such as Market Index and Morningstar, says the company is working to secure the remaining permits needed to develop a mining, crushing and screening operation that would supply titanium- and vanadium-bearing ore to Asian buyers. The January 2026 PFS Update frames the products as HTLO (10–60 mm) and HTFO (3–10 mm) for refractory lining protection in blast furnaces. ### Independent characterisation **What the company does today.** Audalia generates no operating revenue. Its only income is small amounts of bank interest and sundry income. It spends money to advance Medcalf toward a construction decision: drilling, resource and reserve estimation, geotechnical, hydrological and metallurgical studies, approvals and financing negotiations. Development-related spending is capitalised into an exploration and evaluation (E&E) asset, which had a carrying value of A$14.70M at 31 December 2025. Corporate overheads and interest on related-party and private loans go through the profit and loss account. **Intended business model (post-development).** The planned business is a contractor-operated, single-source open-pit quarry. The planned flow is: 1. Open-cut mining with conventional drill-and-blast and 100–200 t excavators, at a low strip ratio of 0.6:1 (waste to ore). 2. Two-stage crushing and screening on site. There is no chemical processing and no tailings storage facility. 3. Road-train haulage of about 220 km to the Port of Esperance. 4. Bulk export of two products, HTLO and HTFO, to steel mills in Asia, with China as the base case. The planned output is 80,000 t per month of combined product (about 0.96 Mtpa) at a targeted 11.5% TiO2 and about 53% Fe2O3, over a 9-year life. **Revenue model.** If developed, revenue would come entirely from product sales: physical bulk commodity sales priced per tonne, with penalties for silica and alumina above specification. The PFS base prices are US$100/t for HTLO and US$90/t for HTFO. There is no service, subscription or licensing component. **Value-chain position.** Upstream raw-material supplier (mine-gate to FOB Esperance). The HTLO and HTFO products are consumables in the iron-making process. Titanium-bearing material is charged to the blast furnace, where titanium carbonitride deposits form in the hearth and protect eroded refractory linings. The products compete with ilmenite lump, titanium pellets and domestic Chinese high-titanium ores. **Customer types and end markets.** The target customers are integrated blast-furnace steelmakers, primarily in China. Audalia commissioned Beijing Zhonglian Bona (China Market Research Net) to study the market. In November 2025 it held preliminary sales negotiations that refined the product specifications and the penalty structure. No binding offtake has been announced. **Historical pivot.** The 2016 PFS by Simulus Engineers envisaged a hydrometallurgical flowsheet producing V2O5, TiO2 pigment-grade feed, iron oxide and a copperas by-product. From about 2022, the company reframed Medcalf as a titanium DSO project, which sharply cut capital intensity and technical risk. Vanadium (0.61% V2O5 in the reserve) is now largely a by-product contained in the iron-titanium ore and is not separately monetised in the PFS base case.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2010
West Perth, Australia
Atomo

Atomo Diagnostics Limited

Premium
Information Technology

Atomo Diagnostics is a micro-cap Australian medical device company that designs, makes and sells integrated, blood-based lateral-flow rapid diagnostic test (RDT) devices for professional point-of-care and self-testing. It has two revenue engines. The first is its own finished tests, chiefly the WHO-prequalified, TGA-approved and CE-marked Atomo HIV Self-Test, sold through Viatris (formerly Mylan) into Global Fund–financed low- and middle-income country (LMIC) programmes, through NFLD in Europe, and through pharmacies and government programmes in Australia and New Zealand. The second is an OEM "Atomo inside" business supplying its patented all-in-one Pascal cassette to diagnostics partners. The flagship OEM customer is Lumos Diagnostics, whose FebriDx bacterial-versus-viral test received US FDA CLIA waiver in March 2026 on the Pascal platform. With FY2026 revenue of A$5.3m (+41%), a narrowing loss, no debt and a pipeline spanning active syphilis, liver function (ALT) and ferritin, Atomo is a sub-scale but differentiated device-platform play. It is in a leadership transition and depends on regular equity raises. --- **Company's own description (FY2026 Annual Report and Results Overview).** The FY2026 Directors' Report defines the group's principal activity as "the development and sale of medical devices." The FY2026 Results Overview calls Atomo "a commercial stage diagnostic company with a growing revenue base from sales of approved professional and self-test point-of-care tests (POCT) across global markets." It says Atomo's solutions deliver usability and reliability that enable decentralised testing. The company describes two businesses: 1. **Atomo Point of Care Test (POCT) Diagnostic Products.** Blood-based rapid tests sold into professional-use and self-test channels globally. The stated focus is a pipeline of "high value, reimbursed diagnostic products for decentralised professional testing." 2. **Point of Care Test Technologies (OEM Business).** Partner sales driven by an FDA-approved, CLIA-waived test (Lumos FebriDx). Atomo supplies an integrated proprietary all-in-one device (Pascal) to partners seeking better usability and performance for blood-based POCT, plus "additional technologies that can integrate with the client's own cassette" (the Florey clip-in device). The company's ASX boilerplate describes it as an Australian-headquartered medical device company supplying integrated RDT devices to the global diagnostic market. Its patented devices simplify testing, improve usability and improve reliability for point-of-care and at-home testing. **Business model and revenue model.** Atomo generates revenue in four reported lines (FY2026 Annual Report, Note 3): By nature, revenue is overwhelmingly product sales. Sale of goods was A$5.23m (98.0%) in FY2026. Services, meaning development and licence fees recognised over time, were A$0.11m (2.0%). There is no subscription revenue. Licensing revenue is episodic: FY2025 included roughly A$340k of one-off licence fees. In the OEM channel, Atomo is paid a transfer price for each Pascal cassette. Management describes Atomo as receiving "a percentage portion of the proceeds based on the transfer price of Pascal" for each FebriDx test sold to PHASE Scientific (FY2026 Results Overview). The P&L is also materially supported by non-revenue government income. FY2026 other income was A$2.23m, comprising the R&D tax rebate (A$1.26m), CRC-P grant income for the Active Syphilis test (A$0.89m) and interest (A$0.08m). That equals 42% of revenue. **Value-chain position.** Atomo sits at the device design and manufacturing layer of the rapid-diagnostics value chain: - It designs and patents the integrated device: lancet, blood collection, buffer delivery and test strip housed in one cassette. - It qualifies tooling, including high-cavitation injection moulds now being qualified, and runs proprietary blister packaging machines. Blister Machine #2 was relocated to an Atomo-operated facility in Sydney in FY2026. - It performs finished-test assembly and packaging at its South African branch. - It relies on third-party manufacturers for certain inputs (FY2026 risk disclosures). - For own products, it holds regulatory registrations (TGA, CE/IVDD/IVDR, WHO PQ) and sells through distributors such as Viatris, NFLD, pharmacy wholesalers and government programmes. - For OEM products, the partner (e.g., Lumos) owns the assay and regulatory file, and Atomo is the "critical supplier" of the device. **Customer types.** Global health procurement intermediaries (Viatris, funded by the Global Fund); European consumer-health distributors (NFLD; historically supplying retailers such as Boots and Tesco); Australian and New Zealand pharmacies and wholesalers (Chemist Warehouse online, CDC in New Zealand); Australian government-funded programmes (e.g., distribution with NAPWHA, the National Association of People with HIV Australia); and IVD companies buying OEM devices (Lumos Diagnostics, Chromacare, an unnamed UK company, and two new OEM customers from January 2026). Customer concentration is extreme: five customers accounted for 92.0% of FY2026 revenue (FY2025: 72.5%). The largest single customer ("Customer E") accounted for 36.2%. The Annual Report does not name it, but given the nine-fold rise in Lumos orders it is likely Lumos; that attribution is an inference. **End-markets served.** (i) HIV self-testing and professional HIV testing (LMIC public health, European retail, Australia/NZ pharmacy and government); (ii) US decentralised professional testing (urgent care, physician office) via CLIA-waived OEM products; (iii) emerging sexual health (active syphilis), liver function monitoring (ALT) and iron deficiency (ferritin); (iv) historically, COVID-19 antibody testing (FY2020–FY2022) and female health/pregnancy. **Independent characterisation.** Atomo is best understood as a device-platform company with a small captive finished-goods franchise. Its intellectual property is ergonomic and mechanical, not biochemical: it solves the user-error problem in finger-stick blood testing. The economic proof point is the FDA CLIA waiver for FebriDx. US trials showed more than 99% concordance between trained and untrained users, and management states the waiver relied on Pascal's performance. That regulatory precedent is arguably Atomo's most valuable asset, because it gives future partners a predicate path into the CLIA-waived and self-test channels. CLIA waiver can expand a rapid blood test's addressable market more than ten-fold (company claim). The business remains sub-scale, however: revenue of A$5.3m, gross margin of 35%, and statutory operating cash burn of A$3.4m in FY2026. Volumes are lumpy and tied to partner order cycles and donor-funded tenders.

Revenue$0.0B
EmployeesN/A
Market Cap$0.0B
Founded2010
Leichhardt, Australia
Atlas

Atlas Arteria Limited

Premium
Information Technology

Atlas Arteria is a specialist owner and active manager of long-dated toll road concessions in France, Germany and the United States. Economically it is overwhelmingly a French motorway business: its 31.14% effective interest in APRR — France's second-largest motorway network, jointly controlled with Eiffage — generates roughly 85% of proportional toll revenue. Around this anchor sit a 66.67% stake in the Chicago Skyway (a 99-year concession with contractual toll escalation), 100% economic ownership of the Dulles Greenway in Virginia (a regulated, politically contested asset), the 100%-owned Warnow Tunnel in Rostock, and the ADELAC (A41) concession in the French Alps. The group's equity story is a high-yield, inflation-linked cash distribution vehicle (40 cps p.a., ~8% yield), constrained by APRR's relatively short concession tail (mid-2030s), French fiscal intervention, and a decade of regulatory stalemate at Dulles. In July 2026 IFM gained majority control via a hostile bid, fundamentally changing the group's governance and strategic optionality. --- ### Company's own description In its current ASX boilerplate, ALX describes itself as a company that partners to deliver world-class road experiences, and states that the group today consists of toll road businesses in France, Germany and the United States (ALX ASX releases, 2026). Its asset description names a 31.14% interest in the APRR Group (APRR, AREA and A79 concessions) and ADELAC in France; a 66.67% interest in the 12.5 km Chicago Skyway; 100% of the economic interest in the 22 km Dulles Greenway in Virginia; and 100% of the Warnow Tunnel in Rostock, north-east Germany (ALX 2025 Results release, 26 Feb 2026). ### Independent characterisation ALX is best understood as a listed holding company of minority and controlling stakes in toll concessions, whose cash flow to securityholders is the residual of a multi-layered chain: 1. **Toll revenue** at each concession (driven by traffic × tariff, with tariffs set by concession formulae or regulators); 2. **EBITDA** at each concession (very high margins, ~75% proportionally); 3. **Asset-level debt service, tax and capex**, which in APRR's case includes French corporate tax, the 2024 long-distance transport infrastructure tax (TEILD) and, from 2025, the Temporary Supplemental Tax (TST) on large companies; 4. **Holding-company debt amortisation** above APRR (the MAF2/"Finance Safari" acquisition debt), which was refinanced in 2024 to reduce amortisation; 5. **Distributions upstream** to ALX corporate, which then pays securityholders after corporate costs. The revenue model is 100% usage-based infrastructure tolling — no product, subscription or licensing revenue of note. Value-chain position: ALX is a concession owner and asset manager, not a constructor; operations at APRR are run by APRR's own management (jointly overseen with Eiffage), while ALX runs Dulles Greenway and Warnow directly and co-controls Chicago Skyway with Ontario Teachers' Pension Plan (OTPP). ### Customers and end-markets | Customer type | Description | Main assets exposed | |---|---|---| | Light vehicles — commuters | Daily commuting traffic; sensitive to work-from-home patterns and alternate-route congestion | Dulles Greenway, Chicago Skyway, Warnow Tunnel | | Light vehicles — leisure/long-distance | Holiday and inter-city traffic, highly seasonal (French summer peaks) | APRR, AREA, ADELAC | | Heavy vehicles (trucks) | Freight traffic tied to industrial production and European trade flows; higher per-km tariffs | APRR (major freight corridors linking Paris–Lyon–Alps–Germany/Switzerland), A79 (heavy vehicles ~69% of 2023 toll revenue per ALX 2023 Results) | | Governments (counterparty, not customer) | Concession grantors: French State, Commonwealth of Virginia (SCC as rate regulator), City of Chicago, German authorities in Rostock | All assets | End-markets served are, in economic terms, road mobility in eastern France and the Alps, the Chicago south-side/Indiana corridor, Loudoun County (Northern Virginia), and Rostock. ### Business-model economics **Inflation linkage:** APRR concession tariffs are linked to French CPI (ex-tobacco), with base increases at 70% of CPI plus negotiated increments tied to capex plans (Morningstar summary of concession terms, 2024). Chicago Skyway tariffs escalate under a contractual formula (the greater of fixed steps, CPI or nominal GDP per capita growth); the weighted average real toll price rose c.5.6% from 1 January 2025 (ALX Q1 2025 update). Dulles Greenway tolls require SCC approval under a statutory "reasonableness to users" test, which has denied the last increase. **Margins:** Proportional EBITDA margin of 75.0% in FY2025 and 76.6% in H1 2026 (ALX releases). **Distribution policy:** pay 90–110% of free cash flow on a full-year basis (introduced February 2025); 40.0 cps paid for each of 2022–2025 and guided for 2026. From August 2026, ALX will no longer provide a quantified distribution target beyond a one-year horizon (H1 2026 Results).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2009
Victoria, Australia
Aspire

Aspire Mining Limited

Premium
Information Technology

Aspire Mining is a pre-revenue, single-asset metallurgical coal developer. Its flagship is the 100%-owned Ovoot Coking Coal Project (mining licence MV-017098) in Khuvsgul aimag, north-western Mongolia. Ovoot hosts a JORC (2012) Total Coal Resource of 219.4 Mt and a Total Coal Reserve of 130.1 Mt (marketable reserve 97.9 Mt). These support a forecast 31-year mine life producing a low-ash "fat" coking coal, classified by China's Fenwei as FM36. Fat coal is scarce in northern China. Aspire also holds 90% of the earlier-stage Nuurstei Coking Coal Project. The company is moving from permitting into construction. It has executed a USD 69.9M EPC contract with CCTEG-IEC for the coal handling and preparation plant and an Erdenet rail terminal. It is negotiating a build-operate-transfer PPP for the Murun–Uliastai Highway and is targeting first coal and exports in Q4 2027. The investment case rests on funding: management plans about USD 126M of Mongolian OTC bonds plus vendor finance. --- ### Company's own description In its latest annual report and quarterlies, Aspire says it is developing premium coking coal deposits in an environmentally sensitive way. It frames this as supporting global sustainable development, sharing prosperity with host communities and delivering long-term shareholder growth. The FY2025 Directors' Report states that the Group's principal activity is progressing studies, permits and approvals to develop the Ovoot Coking Coal Project (AFR FY2025, Principal Activities). The company describes Ovoot as world-class on scale, product quality and economics. It says all major approvals are in place and that the project is on a pathway to production of a sought-after fat coking coal for China and other supply-constrained markets (Quarterly Report Q3 2025, "About Aspire"). ### Independent characterisation Aspire is a development-stage junior miner. It has no operating revenue, no producing assets and no debt. Its only income is interest on cash and bonds (USD 0.24M in FY2025). Its planned business model is vertically integrated: 1. **Mining.** Open-cut mining at Ovoot, starting from a low-ash, high-yield starter pit. Rented mining equipment will be used for the first three years under the September 2026 revised plan. 2. **Processing.** A modular on-site Coal Handling and Preparation Plant (CHPP) will produce washed fat coking coal. The plan uses fully enclosed coal handling and maximum water recovery so that no tailings dam is needed (2025 Annual Report sustainability disclosures). 3. **Logistics.** Washed coal will be trucked about 560 km by road to an Aspire-controlled Erdenet Rail Terminal (ERT). There it will be loaded onto the Trans-Mongolian Railway for delivery to northern Chinese end-users, with onward export options through Caofeidian/Tangshan ports. Road haulage will be contracted for the first five years. The Murun–Uliastai Highway, a BOT PPP, is intended to overlap much of the haul alignment. 4. **Marketing.** Aspire has regained exclusive marketing rights after legacy Noble/Talaxis alliance rights were extinguished in March 2026. In exchange, NordSteppe PIF receives a 0.75% gross sales royalty. Aspire can now negotiate offtake, prepayment and logistics directly with steel mills and coke makers. ### Revenue model and mix | Revenue type | Current status | Future model | |---|---|---| | Product sales (washed coking coal) | Nil (pre-production) | About 100% of future revenue; USD-denominated, CFR/FCA China pricing | | Services | Nil | Not planned as a material line | | Subscription / licensing | Nil | None | | Interest income | USD 0.24M (FY2025); USD 0.69M (FY2024) | Incidental | | Infrastructure (toll / rail) | Nil | Possible minority equity in the Murun–Uliastai Highway SPV, expected to dilute with third-party equity (Q2 2026 quarterly) | ### Value chain position, customers and end-markets Aspire sits upstream in the steel value chain. Its fat coal is a coking coal blend component that gives coke its strength and fluidity. Target customers are independent and state-owned coke makers and integrated steel mills in northern and north-eastern China, including Hebei, Shanxi, Inner Mongolia and Liaoning regions. In 2025 Aspire met end-users in Hebei and logistics firms such as Tangshan Caofeidian Iron and Steel Logistics ("HBIS Wharf"), which ships about 20 Mtpa of bulk commodities through Caofeidian port (Quarterly Report Q3 2025). Secondary seaborne markets, reached via Chinese ports, include Japan, Korea, Taiwan and India. Russia has historically been mentioned as a possible market (2018-era materials), but recent filings focus on China.

RevenueN/A
EmployeesN/A
Market Cap$0.1B
Founded2006
Sydney, Australia
Asiamet

Asiamet Resources Limited

Premium
Information Technology

Asiamet Resources is an AIM-quoted, Bermuda-incorporated and Jakarta-based mineral exploration and development company. For most of the past decade it was one of the few listed juniors offering pure-play exposure to Indonesian copper development. Its flagship was the BKM heap-leach SX-EW copper project inside the 390 km² KSK Contract of Work in Central Kalimantan. In 2025 the company re-engineered BKM into a lower-capex Stage 1 design and then ran a competitive two-phase strategic review. That review ended in the November 2025 agreement to sell the KSK interest to Norin Mining, a subsidiary of China's Norinco Group, for US$105 million on an enterprise-value basis. With the sale completed in September 2026 and roughly 89% of the gross proceeds returned as a special dividend, Asiamet is now a micro-cap holding an 80% interest in the large but socially and legally contested Beutong porphyry copper-gold project in Aceh. The board is openly reassessing the company's strategy. Indonesian mining-services group PT BUMA Internasional Grup Tbk (c.44%) is its controlling shareholder. --- ### Company's own description The interim report for H1 2026 says the group is principally engaged in the exploration and development of mineral properties, with its principal mineral property interests in Indonesia (H1 2026 Interim, Note 1). Before the KSK sale, the company described itself in announcements as an emerging mid-tier exploration and development company focused on copper, copper-gold and polymetallic deposits in Indonesia. Alliance News, drawing on company materials, described it in September 2026 as focused on developing a portfolio of large copper, copper-gold and polymetallic deposits in Indonesia. ### Independent characterisation | Dimension | Characterisation | |---|---| | Revenue model | No revenue. Value was realised through asset sale (KSK, US$105m EV). No product, service, subscription or licensing revenue in any year FY2021–H1 2026 | | Value-chain position | Upstream: exploration, resource definition and feasibility. No mining, processing or marketing operations | | Intended product (pre-sale) | LME Grade A copper cathode from BKM (c.10ktpa design), aimed at Indonesia's downstream copper industry and global energy-transition demand | | "Customers" | Effectively acquirers and strategic investors (Norin Mining, BUMA). Potential offtakers were engaged in earlier financing work (China Zenith Capital mandate, 2023) | | End-markets | Copper: electrification, power grids, EVs, construction. Gold, silver and molybdenum are by-products at Beutong | | Funding model | Repeated equity placements, mainly from BUMA/Delta Dunia, the CEO and existing holders. The KSK sale provided a one-off liquidity event | | Current state (Oct 2026) | A post-disposal holding company with one principal asset (Beutong, 80%) and a modest, undisclosed residual cash balance. Strategy is under review | Asiamet has never generated operating revenue. Its business model was the classic junior-mining value chain: acquire title, define resources, de-risk through feasibility and permitting, then either finance and build a mine or realise value through a sale. The 2025–2026 sequence shows the company chose to sell. The board said explicitly that the strategic review addressed structural and financial constraints inherent in developing large-scale mining assets within the framework of a junior company (Nov 2025 Circular, s.4).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1997
Bermuda
ASF

ASF Group Limited

Premium
Information Technology

ASF Group Limited is a Sydney-based micro-cap investment house. Its purpose has been to facilitate two-way capital, trade and technology flows between Australia and Greater China, and more recently the UK. For most of the past decade it was effectively a highly levered holding company: it held minority stakes in affiliated ASX-listed explorers (ActivEX, Rey Resources, Key Petroleum) and controlled interests in a Queensland coal project (Dawson West, via CMR) and an engine-technology venture (ASFTA). This was funded almost entirely by a related-party-style A$25M convertible facility from Star Diamond Developments. The 27 March 2025 debt-for-asset conversion with Star Diamond, followed by the FY2026 sale of coking-coal tenements and the ASFTA stake, transformed ASF. It went from a A$27M equity deficiency to a debt-free shell with about A$5.2M cash. Its small operating businesses are corporate services, property services (ASF Properties) and an AFSL-holding fund/advisory arm (ASF Capital), which is incubating a pre-commercial digital-asset platform. --- ### Company's own description Across its annual reports and Appendix 4E filings, ASF describes itself as a diversified investment company with an international outlook. Its stated focus is the real estate, resources, technology and financial sectors. The company says it works as a creator and facilitator of strategic trade and investment between Australia and the world. Its fund-management arm, ASF Capital, is described as the vehicle for facilitating two-way capital flows between Australia and Asia (FY2025 and FY2026 Appendix 4E). Data providers that draw on the annual report (Morningstar) record that the company reports a single operating segment: an "investment and trading house." Corporate services generate the substantial share of revenue. ### Independent characterisation On the evidence of the FY2022–FY2026 accounts, ASF is best described as a closely held, cross-border merchant-banking shell in wind-down-and-reset mode. Its economics have three layers. 1. **Recurring fee revenue (small).** Corporate-services fees, recognised over time, were A$0.56–0.78M a year in FY2022–FY2026. These are largely services to affiliated or associated companies; the counterparties are not itemised. 2. **Episodic commission revenue.** Property-marketing commissions are recognised at a point in time. They peaked at A$1.91M in FY2024 on settlement of The Peninsula Hope Island Stage 3 (Gold Coast) and fell to nil in FY2026. 3. **Investment gains and losses (dominant).** Statutory earnings are driven almost entirely by revaluations, impairments, equity-accounted associate losses and disposal gains. Examples are the A$32.7M gain in FY2025 from the Star Diamond debt-for-equity transaction and A$4.8M of disposal gains in FY2026. The underlying operating business has lost money every year. Revenue minus operating expenses (excluding gains, impairments, associates and finance costs) was −A$1.8M in FY2022, −A$5.6M in FY2023, −A$2.9M in FY2024, −A$2.8M in FY2025 and −A$1.5M in FY2026. ### Revenue model mix | Revenue type (A$ M) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---|---| | Corporate services (service, over time) | 0.559 | 0.759 | 0.780 | 0.724 | 0.560 | | Commission revenue (property, point in time) | 1.641 | 0.217 | 1.909 | 0.076 | 0 | | Total revenue | 2.200 | 0.976 | 2.689 | 0.800 | 0.560 | Source: FY2023 4E Note 1 (FY2022–23); FY2025 4E Note 1 (FY2024–25); FY2026 4E Note 1 (FY2026). - Product, subscription and licensing revenue: none. - Value-chain position: an intermediary or facilitator (advisory, introductions, project marketing) and a principal investor. - Customer types: affiliated listed companies (corporate services), property developers (commissions), offshore (predominantly Chinese) investors and migrants (ASF Capital and ASFP), and wholesale investors (proposed funds). - End-markets: Australian residential property (NSW and Queensland), junior resources (Queensland and WA), cross-border corporate advisory, and prospectively institutional digital assets.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1980
Sydney, Australia
Asara

Asara Resources Limited

Premium
Information Technology

Asara Resources is a single-asset West African gold explorer moving toward development. Its value rests almost entirely on the Kada Gold Project in Guinea's Siguiri Basin, which sits about 36 km along the same mineralised corridor as AngloGold Ashanti's Siguiri mine. Between 2024 and 2026 the company changed character. It began as a cash-starved, multi-jurisdiction junior (Golden Rim) holding assets in Burkina Faso, Guinea and Chile. It sold Burkina Faso, kept Chile only as non-core, and raised A$85 million in FY2026. Its first sustained drilling campaign in years more than doubled Kada's resource to 2.08 Moz, with Indicated ounces up more than sixfold. The company now owns 51% of Kada and has a right to reach 75% by funding a Definitive Feasibility Study, which is targeted for end-Q2 2027. Its proposition is a large, shallow, oxide-rich, low-grade open-pit gold system, offered in a high-gold-price environment, from an under-explored but sovereign-risk-heavy jurisdiction. --- ### What the company does Asara explores for gold and evaluates gold deposits. It does not mine, process or sell metal, and it reported no revenue from customers in FY2026 (Appendix 5B line 1.1 is nil for the 12 months to 30 June 2026). Its economic activity consists of four things: - Acquiring and holding exploration permits. - Drilling, sampling and geological modelling to define JORC-compliant Mineral Resources. - Technical, environmental and economic studies (a DFS is under way at Kada). - Corporate transactions, including farm-ins, earn-ins, divestments and option/JV agreements, to monetise or fund assets. Its income is interest on cash: A$0.52 million received in FY2026 per the Appendix 5B. It has also received occasional sale proceeds, such as US$2.2 million for the Burkina Faso assets agreed in July 2024. ### Company's own description (paraphrased from FY2025/FY2026 filings) In its standard announcement boilerplate, Asara describes itself as an ASX-listed explorer with advanced mineral projects in Guinea and Chile. Kada is its flagship. It owns 51% of Kada and in April 2022 exercised a right to earn a further 24% (to 75%) by funding a DFS. It describes Guinea as one of West Africa's most under-explored countries and says most of the roughly 150 km² project area remains lightly explored. It also notes that it holds the Paguanta copper/silver-lead-zinc project in Chile, which it is seeking to divest, and that Teck Resources Chile can earn up to 75% of the adjacent Loreto copper project under a US$17 million option and JV agreement. ### Business and revenue model | Model element | Asara's position | |---|---| | Product vs service vs subscription vs licensing | Not applicable today. The future model would be sale of gold doré from an owned and operated mine, or monetisation of the asset through a sale, JV or streaming/royalty financing. | | Current funding model | Equity placements: A$25 million in July–September 2025 at A$0.05, and A$60 million in May–July 2026 at A$0.125. Asset sales (Burkina Faso, US$2.2 million). Partner-funded exploration (Teck at Loreto). | | Value-chain position | Upstream greenfield/brownfield exploration and resource definition, moving into feasibility. | | Customer types | None currently. A future gold producer would sell to refiners and bullion banks; gold is a globally fungible commodity. | | End-markets | Gold, used for investment, central-bank reserves, jewellery and technology. Copper and base metals through the residual Chile interests. | ### Independent characterisation Asara is best understood as a levered option on Kada's eventual Ore Reserve and on the gold price, discounted for Guinea sovereign risk and for JV structure risk. The 2025–2026 drilling programme was large for a junior: 81,361 m at Massan, with up to six rigs running at peak. It was designed explicitly to convert Inferred ounces to Indicated, so that a DFS can be built on them. That makes Asara a "resource-to-study" story rather than a pure discovery play. The company also has a discovery angle: six drill-ready satellite targets and eight auger targets lie within 5–20 km of Massan, and about 95% of drilling to date has been concentrated at Massan (per the 31 Aug 2026 MRE announcement). The Arafura acquisition (Damissa Koura and Kankan West) and four pending 100%-owned permit applications reflect an aim to consolidate a district.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1987
Subiaco, Australia
Aruma

Aruma Resources Limited

Premium
Information Technology

Aruma Resources is a micro-capitalisation, pre-revenue mineral explorer. In late 2025 and 2026 it moved from being a Western Australia–centric gold, lithium and rare-earths prospector to a copper-focused company anchored on the Tillex Copper-Silver Project in the Timmins district of Ontario, Canada. Tillex is a shallow, historically drilled, volcanogenic-massive-sulphide-style (VMS-style) copper-silver system. Aruma acquired an 85% interest (and 100% of adjoining patents) in February 2026. Its own 2026 diamond drilling returned intersections of up to 89m @ 2.04% Cu and 12.31 g/t Ag. The company also holds early-stage copper (Mt Isa, Queensland), heavy-mineral-sands/uranium (Wilan, South Australia), and gold/multi-commodity (Saltwater, Salmon Gums, Melrose, WA) tenure. The investment proposition is a single-asset discovery and resource-definition story: Aruma aims to convert historical and new drilling into a maiden JORC Mineral Resource. That path is constrained by a balance sheet of under A$1m at 30 June 2026 and a reliance on highly dilutive equity raisings. --- ### Company's own description In its 2026 ASX announcements, Aruma describes itself as an ASX-listed, copper-focused exploration company. It states that it explores and develops prospective projects in world-class mineral belts, with the Tillex Copper-Silver Project in Ontario as its core asset. It also lists copper exploration assets in Queensland's Mt Isa region and multi-commodity projects in South Australia and Western Australia (boilerplate "About Aruma", ASX announcements 1 Jul, 12 Aug and 17 Sep 2026). The H1 FY2026 directors' report describes a portfolio of strategically located projects in high-demand commodities across Canada and Australia. Its segment note, prepared at 31 December 2025, still identifies a single segment: mineral exploration in Australia. ### Business model and revenue model Aruma has no operating revenue and no product, service, subscription or licensing income. Its "other income" consists of: - Australian Research & Development Tax Incentive refunds: A$458,677 (FY2022), A$837,176 (FY2023), A$1,146,363 (FY2024), and A$445,126 received in H1 FY2026 for the 2025 claim. - Bank interest: A$113,128 in FY2024; A$4,552 in H1 FY2026. - Occasional asset-sale proceeds: A$70,000 from divesting the non-core Mt Deans Project in H1 FY2026. The economic model is the standard junior-explorer cycle: 1. Acquire tenure cheaply, largely with shares, deferred milestone payments and royalties. 2. Spend equity capital on geophysics, geochemistry and drilling. 3. Generate news flow and, if successful, a JORC/NI 43-101 resource. 4. Monetise value through a re-rating, joint venture, sale or eventual development. Value creation is measured in drill metres, assay grades and resource tonnage rather than revenue. ### Value-chain position and end-markets Aruma sits at the very upstream end of the metals value chain (greenfield and brownfield exploration). It has no mining, processing or offtake. The relevant end-markets are global copper (electrification, grid and EV demand), silver (industrial/photovoltaic and investment demand), and secondarily gold, heavy mineral sands (zircon, rutile, ilmenite) and uranium. Its "customers" today are effectively equity investors. Prospective future counterparties are acquirers or joint-venture partners among mid-tier and major miners. Vale Canada already holds 12% of the core Tillex patent claims. ### Independent characterisation Analytically, Aruma is a single-asset, early-stage resource-definition play wrapped in a legacy portfolio of option-value tenements. Since February 2026, almost all technical and capital allocation has gone to Tillex. Australian projects have received low-cost desktop reviews and sampling only. The Tillex acquisition rescued a strategy that, between FY2021 and FY2025, cycled through gold (Salmon Gums, Melrose, Saltwater, Carter Well), lithium (Mt Deans), rare earths (Salmon Gums, Saltwater), uranium/IOCG (Wilan), and copper (Fiery Creek, Bortala) without producing a resource. During that period the share price fell from A$0.066 (30 June 2022) to A$0.009 (30 June 2025). The key differentiator of Tillex versus the earlier portfolio is twofold. First, about 10,284m of historical diamond drilling by prior owners de-risks the existence of mineralisation. Second, the near-surface geometry (below roughly 25–45m of glacial till) is attractive for potential open-pit economics. The key weakness is financial capacity: cash of about A$0.82m at 30 June 2026 against a roughly 3,600m Phase 2 program, with a A$3.5m raise at A$0.0045 per share (August 2026).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2010
Cottesloe, Australia
Arrow

Arrow Minerals Limited

Premium
Information Technology

Arrow Minerals is a Perth-based, pre-revenue exploration and development company that has reinvented itself three times in five years: from a Western Australian gold-nickel-lithium explorer, to a Guinea-focused bulk-commodities developer (Simandou North iron ore and Niagara bauxite), and — after Guinea's 2025 mass permit revocations froze its flagship assets and forced a year-long ASX suspension — to a hybrid West Africa/West Pilbara explorer. Its current portfolio comprises a newly re-granted three-year exploration permit over the 185Mt Niagara bauxite resource in Guinea, an unresolved permit position at Simandou North, an 80% interest in the historic Yarraloola copper-gold project in WA's West Pilbara, and a 70% earn-in to channel-iron (Robe-style) DSO targets adjacent to Rio Tinto's Robe River operations. Led by Atlas Iron founder David Flanagan, Arrow's investment case rests on management's bulk-commodity development pedigree and proximity to tier-one infrastructure, offset by acute sovereign, funding and dilution risk. --- **What the company does.** Arrow is a mineral exploration company. It acquires early-stage tenure in districts with established or emerging infrastructure, defines mineralisation through mapping, geophysics and drilling, and seeks to advance projects through resource estimation, scoping studies and permitting towards a development decision or a monetisation event. The company does not produce, sell or process minerals and has no operating revenue. **Company's own description.** Data providers carrying Arrow's latest self-description state that the company is engaged in the discovery and development of economic mineral deposits in West Africa, holds the Niagara Bauxite Project and the Simandou North Iron Project in Guinea, and is organised into a single operating segment — exploration (Morningstar company profile, FY2026 data). Arrow's own boilerplate in 2026 ASX releases describes it as an explorer and developer focused on economic iron, bauxite, copper and gold deposits across West Africa and Western Australia. Arrow's FY2022 annual report framed its objective as becoming a producer of top-quartile-quality iron ore for a greener global steel industry, centred on the Simandou Range. **Business model and revenue model.** Arrow's model is the classic junior-explorer "value-creation through discovery" model: **Value-chain position.** Upstream exploration — the earliest and highest-risk stage of the mining value chain. Arrow sits before resource definition (Yarraloola, Pilbara iron), at resource stage (Niagara: Mineral Resource Estimate declared March 2025; scoping study completed but unreleased), or at exploration-target stage (Simandou North). **Prospective customer types and end-markets.** If projects reach production, the end-markets would be: (1) seaborne bauxite buyers, predominantly Chinese alumina refineries, which import the bulk of Guinea's output; (2) seaborne iron ore buyers, chiefly Chinese steel mills — Arrow signed a non-binding MOU with Baosteel Resources (a Baowu Group subsidiary) for potential mine-gate sales from Simandou North; (3) copper concentrate buyers/smelters for any Yarraloola discovery. **Independent characterisation.** Arrow is best understood today as a management-led option vehicle rather than an asset-led developer. The 2025 Guinea permit crisis demonstrated that its two most advanced assets were hostage to sovereign decisions outside its control. Its 2026 pivot back to Western Australia (Yarraloola copper; Robe-style iron) diversifies jurisdictional risk and leverages David Flanagan's Pilbara iron ore credibility from Atlas Iron, but it also means the company is again at the grassroots stage in WA, with no resources there. The balance sheet (cash A$3.36–3.37M at 30 June 2026; net assets A$3.64M) is small relative to work commitments (e.g., US$1.51M minimum spend at Niagara over three years), so dilution is a structural feature of the model.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2005
West Perth, Australia
Arovella

Arovella Therapeutics Limited

Premium
Information Technology

Arovella Therapeutics is a Melbourne-based, ASX-listed micro-cap biotechnology company. It became a clinical-stage company in calendar 2026 and is developing allogeneic ("off-the-shelf") cell therapies based on invariant Natural Killer T (iNKT) cells. The platform was in-licensed from Imperial College London in 2021, when SUDA Pharmaceuticals pivoted away from oro-mucosal drug delivery. The lead asset, ALA-101, is a CD19-directed CAR-iNKT cell therapy. Its US FDA IND was accepted in January 2026, it received Australian ethics approval in June 2026, and its first clinical batch was released in September 2026. First-patient dosing in a Phase 1 trial at The Alfred, Melbourne, is now guided for late October 2026. Behind it sits ALA-105, a CLDN18.2-targeted CAR-iNKT product for gastric and pancreatic cancer armoured with IL-12-TM technology, plus an emerging autoimmune strategy built on CD19 B-cell depletion. Arovella is one of very few companies globally advancing CAR-iNKT cells. It has no product revenue, held A$14.4m of cash at 30 June 2026, and went through a shareholder-driven board overhaul in April–May 2026. --- ### Company's own description (FY2026 Annual Report, paraphrased) The FY2026 Annual Report gives the principal activity as development of the company's iNKT cell platform for treatment of cancer. Management describes the platform as a next-generation allogeneic cell therapy with potential uses in blood cancers, solid tumours and selected autoimmune diseases. iNKT cells are a naturally occurring immune subset. They can kill cancer cells directly, reshape the tumour microenvironment and recruit other immune effectors. When engineered with a chimeric antigen receptor (CAR), they keep these innate and adaptive functions and carry a low risk of graft-versus-host disease (GvHD). That low GvHD risk is what allows donor-derived, batch-manufactured dosing. The stated strategy is a modular CAR-iNKT platform. A proprietary, semi-automated, patent-protected and FDA-cleared manufacturing process is combined with interchangeable CAR targets (CD19, CLDN18.2, others under evaluation), armouring modules (IL-12-TM) and complementary technologies (allo-defence, iNKT agonists). The aim is to create barriers to entry through know-how, IP and trade secrets. Management frames value creation through three workstreams: blood cancers (ALA-101), solid tumours (ALA-105 plus IL-12-TM) and autoimmune disease (ALA-101 repurposed for B-cell depletion). ### Independent characterisation Arovella is a single-segment, pre-revenue, platform-stage cell-therapy developer whose investment value rests almost entirely on one binary near-term readout: first-in-human safety, pharmacokinetic and B-cell-depletion data from ALA-101. It does not manufacture in-house at GMP scale. Clinical material is produced through a contract manufacturer (Cell Therapies Pty Ltd, CTPL, in Melbourne), and the trial is run through a contract research organisation (SAPRO). That makes it an asset-light "virtual-plus" biotech with a small in-house research laboratory (Jumar Bioincubator). Its IP rests mostly on in-licensed rights (Imperial College London for iNKT and IL-12-TM; SparX Group for the CLDN18.2 binder; MD Anderson for DKK1), plus its own manufacturing-process patents and know-how. The legacy SUDA business, which reformulated established drugs as oral sprays on the OroMist platform, is no longer strategically relevant. ZolpiMist (zolpidem oral spray) licensing generated small, irregular revenues through FY2023 and none in FY2026. ### Business model and revenue model | Dimension | Current state (FY2026) | Intended future state | |---|---|---| | Product revenue | Nil | Commercial sales of approved CAR-iNKT products, or royalties from a partner | | Service revenue | Nil | Not a stated strategy | | Subscription revenue | Nil | Not applicable | | Licensing revenue | Nil in FY2026. A$136,000 revenue from contracts with customers in FY2025 (nature not specified in sources reviewed; historically ZolpiMist-related licensing) | Out-licensing or regional partnering of ALA-101/ALA-105 (business development is an explicit board priority) | | Non-operating income | R&D Tax Incentive A$3.50m; interest income A$0.80m (FY2026) | R&D Tax Incentive remains material while R&D is Australia-based | ### Value-chain position Arovella sits at the discovery-to-early-clinical development stage of the oncology and cell-therapy value chain: **Upstream:** academic licensors (Imperial College London; MD Anderson; SparX Group); lentiviral vector and reagent suppliers (the company had SEK-denominated liabilities at 30 June 2026, implying at least one Swedish vendor); healthy-donor blood collection. **Midstream (Arovella's own role):** CAR design and integration, process development (Jumar laboratory), regulatory filings (FDA IND; TGA CTN), clinical strategy and translational science. **Outsourced midstream:** GMP manufacturing (CTPL), clinical operations (SAPRO), and trial sites (The Alfred, with other Australian and New Zealand sites in start-up). **Downstream (future):** marketing approval, reimbursement and commercialisation, most likely through a large-pharma partner given the company's scale. ### Customer types and end-markets There are no paying customers today. The prospective end-markets are: 1. **Haematological malignancies:** relapsed/refractory CD19-positive non-Hodgkin lymphoma (NHL) and certain leukaemias. Payers would be hospital systems and national reimbursement bodies, with treating haematologists and cellular-therapy centres as prescribers. 2. **Solid tumours:** CLDN18.2-positive gastric and gastro-oesophageal junction cancer, and pancreatic cancer. 3. **Autoimmune and neuro-immunological disease:** B-cell-driven disorders. Stiff-person syndrome (SPS) is named explicitly as an example of high unmet need.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1999
Preston, Australia
Aron

Aron Universal Limited

Premium
Information Technology

Aron Universal Limited is a founder-led Indian specialty colourant manufacturer whose business is concentrated almost entirely in one niche: daylight fluorescent pigments and the inks, toners and dispersions derived from them, sold under the FLAMINGO brand. From a single manufacturing base at Jigani on the southern edge of Bengaluru, the company describes itself as India's largest producer and exporter in this niche, shipping to more than 60 countries. It occupies the middle of the value chain, converting dyes and resins into pigment powders, pastes and liquid dispersions that ink makers, paint formulators, masterbatch compounders and textile printers then process further. Its differentiation rests on five decades of formulation know-how, a government-recognised research unit, formaldehyde-free and low-formaldehyde grades, and regulatory credentials for Western markets. Its constraints are modest scale, single-site dependence, promoter concentration and a very limited public disclosure record, including a long-running non-cooperation flag from its rating agency. --- **What the company does.** Aron Universal manufactures daylight fluorescent colourants. These are organic pigments made by dissolving fluorescent dyes in a polymer resin carrier, which is then ground to a fine powder or dispersed in a liquid. The result is a colour that appears markedly brighter than conventional pigment because it re-emits absorbed light. CRISIL describes the product range as fluorescent pigments, colour concentrates and dispersions, used in paints, plastics, textiles, inks, cosmetics, traffic cones and coatings (CRISIL, February 2018). **The company's own description.** The company's website states that it is India's largest manufacturer and exporter of daylight fluorescent pigments, ink bases, toners and dispersions, in business since 1974, headquartered in Bengaluru and exporting to more than 60 countries (company website, page modified February 2026). The home page uses the figure of 65 countries, and the .in site uses 55; CRISIL recorded about 59 countries in fiscal 2017. These are consistent with gradual expansion, but none is audited. **Independent characterisation.** Aron is a small, single-product-family specialty chemicals manufacturer. Its revenue is entirely product sales; no service, subscription or licensing revenue is disclosed. The model has three notable features. First, it is export-led. CRISIL reported that roughly 55 percent of revenue came from exports in fiscal 2017 and that a slowdown in Europe had held back growth. Second, domestic sales are channelled through intermediaries: CRISIL recorded 35 distributors across India, with domestic sales made only through them. Third, the business is formulation-intensive rather than capital-intensive. Product performance depends on resin chemistry matched to the customer's process (water-based, solvent-based, plastics at different moulding temperatures), which is why the catalogue is organised as a matrix of product series against applications. **Revenue model mix.** **Value chain position.** Upstream are suppliers of fluorescent dyes, melamine- and other resin intermediates, and solvents (specific suppliers are not publicly disclosed). Aron sits at the pigment-synthesis and dispersion stage. Downstream are industrial formulators: printing-ink makers, paint and aerosol producers, masterbatch and plastics processors, textile printers and dyers, paper coaters, stationery and art-material makers, and candle, wax and cosmetics producers. **Customer types and end-markets.** Customers are business-to-business. No customer names, concentration figures or contract terms are publicly disclosed. End-markets named by the company are textiles, paper, plastics, printing inks, paints, coatings, wax and graphic arts, with specialist uses in security and anti-counterfeit inks, crack and leak detection (non-destructive testing), and fugitive colours for forest-fire applications.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1974
Bengaluru, India
Argosy

Argosy Minerals Limited

Premium
Information Technology

Argosy Minerals is a Perth-headquartered lithium brine developer. Its main asset is a 77.5% equity interest (earning to 90%) in Puna Mining S.A., which owns 100% of the Rincon Lithium Project on the Salar del Rincon in Salta Province, Argentina, inside South America's "Lithium Triangle." Argosy is one of very few ASX juniors to have actually produced and exported battery-quality (>99.5%) lithium carbonate. It did so from a 2,000tpa demonstration facility, which it suspended in 2024 when lithium prices collapsed. The company is now advancing a Definitive Feasibility Study (DFS) for a 12,000tpa operation. The DFS uses a two-stage flowsheet: solid lithium chloride on site (Stage 1a), then conversion to battery-grade carbonate or hydroxide (Stage 1b). The project is supported by a 731,801t LCE JORC resource and a planned 40MW grid connection. Argosy also holds the 100%-owned Tonopah lithium brine claims in Nevada, near Albemarle's Silver Peak. The investment case depends on funding, since the company held about A$2m cash at June 2026 against a capital requirement many times its market value. --- ### What the company does Argosy explores for and develops lithium brine projects. Its stated principal activity in FY2025 was developing the Rincon Lithium Project in Argentina and exploring the Tonopah Lithium Project in the USA. Directors reported no significant change in that activity during the year (FY2025 AR, Directors' Report). The company describes itself as committed to building a sustainable lithium production company that is heavily leveraged to forecast growth in the lithium-ion battery sector (FY2025 AR, paraphrased). ### Business model and revenue model **Current state:** Argosy is pre-commercial. Group revenue in FY2025 consisted only of interest income of A$179,480 (FY2024: A$337,462). Lithium carbonate sales are booked inside the equity-accounted joint venture, Puna Mining S.A., not in Group revenue. Puna's translated revenue was A$829,090 in FY2025 and A$448,280 in FY2024 (FY2025 AR Note 11). This came from spot sales of stockpiled carbonate produced by the suspended 2,000tpa facility. **Target model:** The company plans to be an integrated upstream producer selling physical lithium chemicals. The products would be lithium chloride intermediate (Stage 1a) and/or battery-quality lithium carbonate or hydroxide (Stage 1b), sold under offtake agreements to battery-chain buyers or traders. Product revenue would be 100% of sales; there is no service, subscription or licensing revenue. Management has repeatedly said it seeks offtake-linked prepayment funding from a tier-1 electric vehicle (EV) or battery-chain counterparty (Mining Weekly, 24 May 2024). **Pricing:** Historical spot sales were priced against benchmarks, such as the Shanghai Metals Market (SMM) battery-grade lithium carbonate price, with FOB Buenos Aires delivery. The June 2025 sale required a 30% deposit with the balance due before loading (Mining Technology, 30 June 2025). ### Value-chain position Argosy sits in the upstream extraction and primary chemical-conversion segment. Its chain runs from brine abstraction to solar/forced evaporation and concentration, then solvent-extraction purification, crystallisation of lithium chloride, and finally optional conversion to carbonate or hydroxide. Downstream customers are cathode-material makers, battery cell manufacturers and chemical traders. ### Customer types and end-markets Disclosed counterparties for spot sales include: - an unnamed Korean chemical company (2020 pilot product; 2024 spot sale) - a Hong Kong-based chemical company (20t, around March 2025) - Hong Kong CB Supply Chain (60t, June 2025) - Chengdu Chemphys Industry, China (16.1t, around November–December 2025) Strategic shareholder Amperex Technology Limited (ATL), a TDK group battery manufacturer, agreed in May 2024 to negotiate a potential offtake in good faith. No binding long-term offtake has been disclosed. End-markets are lithium-ion batteries for EVs and stationary energy storage (ESS). ### Independent characterisation Argosy is a single-asset, minority-funded (by value), Argentina-exposed brine developer. It has an unusual technical credential: it achieved commercial-grade product from a small plant. It now faces an equally unusual strategic problem. The proven 2,000tpa solar-pond flowsheet has been set aside in favour of a new, unproven-at-scale solvent-extraction/lithium-chloride route for a 12,000tpa project. That project's capex is not yet published but is certain to be orders of magnitude above the company's market value. The share register is about 80% retail (Simply Wall St). Funding has come in small, highly dilutive tranches (A$2m at A$0.025 in July 2025; A$3m at A$0.036 in September 2026).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1985
Perth, Australia
ArenaREIT

Arena REIT

Premium
Information Technology

Arena REIT is an internally managed, ASX 200 Australian REIT that develops, owns and manages social infrastructure property. Its portfolio is overwhelmingly early learning centres (ELCs), supplemented by a small healthcare book. At 30 June 2026 it held 307 properties valued at A$1.96bn, with 100% occupancy and a 17.5-year weighted average lease expiry (WALE). Leases are typically triple-net, long-dated, with fixed or CPI-linked annual reviews and periodic market reviews, and are backed by tenant bank guarantees and cross-default provisions. The investment case is "bond-like" growth: contracted rent escalation, plus a self-originated development pipeline delivering roughly 6% yields on cost, all funded by a conservative balance sheet (24.5% gearing, 100% hedged). That case was tested in August 2026, when tenant Edge Early Learning (14% of rent) defaulted and entered administration. The default exposed Arena's concentration in a sector facing falling enrolments, heavier regulation and operator stress. --- ### Company's own description Arena describes itself as an ASX 200 listed property group that develops, owns and manages social infrastructure properties across Australia, with a portfolio leased to a diversified tenant base in the early learning and healthcare sectors (FY2026 Results Announcement, 21 Aug 2026). Its stated investment objective is to generate an attractive and predictable distribution for securityholders, with earnings growth prospects over the medium to long term (FY2026 Directors' Report). Its corporate purpose is "Better Communities. Together." The FY2026 Directors' Report lists the sectors the group will consider: - early learning and childcare - healthcare: medical centres, diagnostic facilities, hospitals, disability accommodation, aged care - education: schools, colleges, universities In practice, capital has been deployed almost entirely into ELCs. ### Business model Arena is a pure-play landlord and developer. It does not operate childcare or healthcare services. Revenue comes from four mechanisms: 1. **Rental income from operating properties.** Long-term operating leases, rent paid monthly, typically triple-net (tenants bear outgoings, maintenance and most capital costs). Property expenses are therefore tiny: A$0.8m against A$101.6m of property income in FY2026 (Directors' Report). 2. **Contracted rental growth.** Annual fixed or CPI-linked reviews, plus periodic market rent reviews. In FY2026 like-for-like rent rose 4.0% on average; 36 market reviews averaged +7.6% (FY2026 Results Announcement). 3. **Development.** Arena acquires land or funds-through ELC projects pre-leased to operators, typically on 20-year initial leases. It capitalises interest during construction at fund-through rates of 5.75%–6.5% (FY2026 Note 3) and earns a development margin through revaluation on completion. In FY2026, 11 projects were completed for A$87m at a 6.0% weighted average net initial yield on cost. 4. **Capital recycling.** Older or lower-growth centres are sold, typically at premiums to book (11 ELCs sold for A$53.5m at an 8% premium in FY2026), and proceeds are redeployed into new-build assets. ### Revenue mix | Revenue type | FY2026 (A$000) | Share of total operating income | Source | |---|---|---|---| | Property income (cash/distributable basis) | 101,569 | 98.5% | FY2026 Directors' Report | | Interest income | 1,534 | 1.5% | FY2026 Directors' Report | | Total operating income | 103,103 | 100% | FY2026 Directors' Report | | Straight-lining of rent (statutory, non-cash) | 14,155 | n/m | FY2026 Note 8(c) | | Statutory property income (incl. straight-line) | 115,724 | n/m | FY2026 P&L | In the product / service / subscription / licensing framing: revenue is 100% service-like contracted lease income. There is no product, subscription or licensing revenue. Minimum non-cancellable lease receivables totalled A$2.29bn at 30 June 2026, of which A$101.9m falls due within one year (FY2026 Note 8(g)). ### Value chain position Arena sits between capital markets and service operators. It: - originates sites and partners with developers or builders - funds construction - leases completed assets to operators (Goodstart, Green Leaves, Edge, Aspire, Affinity, G8 Education and others) - manages the assets over 20+ year leases The tenant's ability to pay depends largely on federal funding: the Child Care Subsidy (CCS) for ELCs, and Medicare or state health funding for the healthcare tenants. ### Customer types and end-markets | Customer (tenant) | Type | % of portfolio income (30 Jun 2026) | |---|---|---| | Goodstart Early Learning | Not-for-profit company limited by guarantee | 19% | | Green Leaves Early Learning | Private ELC operator (~70 centres) | 16% | | Edge Early Learning | Private ELC operator (>60 centres); in voluntary administration since 25 Aug 2026 | 14% | | Aspire Education | Private ELC operator (>30 centres, VIC/WA/NSW) | 11% | | Affinity Education Group | Private ELC operator (>240 centres) | 11% | | Limestone Bidco (ForHealth) | Private healthcare operator | 5% | | G8 Education | ASX-listed ELC operator | 4% | | Bendigo Health Care Group | Victorian public health service | 2% | | SACare | Private (healthcare/aged-care related) | 2% | | YMCA Learning Communities | Not-for-profit ELC operator | 2% | Source: FY2026 Financial Report, Note 8(d). The top five tenants account for 71% of income. **End-markets:** Australian long day care (early childhood education and care, ECEC), plus specialised healthcare: medical centres, day hospitals, and specialist disability or health service facilities. ### Independent characterisation Arena behaves like a long-duration, inflation-linked infrastructure-style credit on a pool of childcare operators. Its economics depend on three things: - the spread between its ~5.5% passing yield and a ~4.2% all-in cost of debt - 3–5% contracted rent escalation - the ability to originate new-build ELCs at ~6% yields on cost The structural vulnerability is that tenants are thinly capitalised private operators. Rent is affordable at portfolio level (rent is 10.0% of centre revenue; EBITDAR/rent cover is 3.05x), but operator-level leverage and corporate overheads can still trigger defaults, as Edge demonstrated. The business is therefore less "bond-like" than its 17.5-year WALE implies. Lease length protects valuation and income only as far as the tenant's balance sheet, the bank-guarantee pool and re-letting prospects allow.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2003
Melbourne, Australia
LacGold

Lac Gold Limited

Premium
Information Technology

Lac Gold Limited is a Perth-headquartered, ASX-listed gold explorer whose value rests almost entirely on Canadian assets. The company was reshaped in December 2025 when Ardiden Limited — a cash-rich shell-like explorer that had monetised its Ontario lithium interests and was holding a largely dormant Pickle Lake gold package — acquired the private Lac Gold Limited and with it the Rouyn Gold Project on the Cadillac–Larder Lake Break in Québec's Abitibi belt. Rouyn carries a 1.66Moz resource at 3.28 g/t, roughly 59% in the Indicated category, located about 4km from the mining city of Rouyn-Noranda and among operating mills owned by Agnico Eagle, IAMGOLD and Eldorado. In 2026 the company drilled more than 24,700m at the Astoria deposit, added Barrick's former Golden Patricia mine in Ontario for no cash, and rebranded as Lac Gold. Its investment case is resource growth, re-rating of a low enterprise value per ounce, and strategic relevance to nearby mill owners — set against a looming vendor-debt instalment and an inevitable need for further equity. --- ### What the company does Lac Gold explores for, defines and seeks to advance gold deposits toward development in Canada. It does not mine, process or sell gold. Its activities comprise diamond drilling, geological modelling, mineral resource estimation, metallurgical test work, environmental baseline studies, permitting, and community and First Nations engagement. Its two project areas are: 1. **Rouyn Gold Project (Québec)** — the flagship. 73 contiguous mining claims plus one mining concession hosting four deposits/project areas (Astoria, Augmitto, Cinderella, Gamble), established surface infrastructure and a 29-year lease over surface rights in key areas (HY2026 Report, Note 8; ASX 31 Aug 2026, JORC Table 1). 2. **Pickle Lake Gold Project (Ontario)** — a district-scale claim package in the Uchi Subprovince, now incorporating the historic Golden Patricia mine (acquired from a Barrick subsidiary, completed 9 June 2026), plus the Kasagiminnis, Dorothy and Dobie deposits and numerous prospects. The tenement schedule also lists a residual Manitouwadge graphite claim group (June 2026 Quarterly tenement schedule). ### Company's own description The latest primary description (June 2026 Quarterly, 30 July 2026; repeated in the 31 August 2026 announcement) characterises the company as a Canadian-focused gold company advancing Rouyn in Québec and Pickle Lake in Ontario, emphasising disciplined project advancement through targeted exploration, technical evaluation, responsible development and local partnerships. The June 2026 Quarterly states the strategy in three parts: grow and advance Rouyn; systematically assess and unlock value at Pickle Lake; and allocate capital and management attention to the opportunities with the greatest potential for shareholder value. The FY2025 Annual Report (pre-merger, Ardiden) described the company as solely focused on gold exploration at Pickle Lake after selling its lithium project to Green Technology Metals over 2021–2023. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | None from operations. Income consists of interest on cash deposits (FY2025: A$0.513M; FY2026 interest received A$0.503M per Appendix 5B) and mark-to-market movements on a residual listed shareholding in Green Technology Metals (ASX: GT1) | | Product / service / subscription / licensing mix | Not applicable – 0% of each | | Monetisation pathways (prospective) | (a) Sale of the company or a project to a producer; (b) ore-sale or toll-milling arrangements with nearby Abitibi mill owners; (c) standalone mine development; (d) joint venture / farm-out; (e) royalty or stream financing | | Funding model | Equity placements, option exercises, interest income, and historically asset sales (GT1 lithium consideration). Vendor finance (Yorbeau note) embedded in the Rouyn acquisition | | Value chain position | Upstream: exploration and resource definition, the earliest and highest-risk stage of the mining value chain | | Customer types | No customers. Prospective counterparties are gold producers operating mills in the Abitibi (Agnico Eagle, IAMGOLD, Eldorado named in company materials), and capital providers | | End-market | Global gold market (investment, central bank, jewellery and industrial demand), accessed only indirectly via asset value | ### Independent characterisation Analytically, Lac Gold is best understood as a leveraged call option on (i) the gold price and (ii) the conversion of drilling success at Astoria into a larger, higher-confidence resource, with a secondary, longer-dated option on Pickle Lake. Three structural features distinguish it from the typical ASX gold junior: **Brownfields rather than greenfields:** Rouyn has over 100 years of exploration and production history, with 2,428 historical diamond holes for 436,678m (ASX 31 Aug 2026, JORC Table 1). Limited mining last occurred in 1988 when gold averaged roughly US$440/oz (ASX 30 Jun 2026). The resource was defined to only about 400–700m depth, whereas neighbouring Cadillac Break operations mine toward 3,000m (HY2026 Directors' Report). **Infrastructure-rich location:** The project sits immediately south of Rouyn-Noranda (population cited by management at ~45,000) with power, roads, rail and an airport, and among mills that management describes as under-utilised (MiningNews partner content, 7 Aug 2026, citing Blue Ocean Equities). **Unusual capital structure for a junior:** It carries C$20M of vendor debt at 5%, which converts what would otherwise be a well-cashed explorer into one facing a fixed C$6.67M principal call in December 2026.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2004
West Perth ", Australia
Ardea

Ardea Resources Limited

Premium
Information Technology

Ardea Resources is a Perth-based critical-minerals developer. Its main value is control of the Kalgoorlie Nickel Project, which the company describes as Australia's largest nickel-cobalt resource and among the largest in the developed world: 854Mt at 0.71% Ni and 0.045% Co, containing about 6.1Mt nickel and 386kt cobalt. Its development strategy is concentrated on the Goongarrie Hub, a planned multi-decade, open-pit, acid-leach laterite operation. The 2023 Pre-Feasibility Study targeted roughly 30ktpa nickel and 2ktpa cobalt over a mine life of more than 40 years. The Goongarrie Hub is being de-risked through an incorporated joint venture in which Sumitomo Metal Mining and Mitsubishi Corporation have funded a A$98.5M Definitive Feasibility Study in exchange for 35% equity, rising to 50% on a positive Final Investment Decision. Ardea is effectively a carried, majority-owned project developer with optional upside in scandium, rare earths and nickel sulphide exploration. Its valuation is driven by DFS outcomes, nickel price expectations and project financing rather than by earnings. --- ### What the company does Ardea explores for and evaluates mineral deposits in the Eastern Goldfields of Western Australia, with a single development objective: to bring the KNP Goongarrie Hub nickel-cobalt laterite deposits into production. Its activities fall into four areas: 1. **Feasibility and development (Goongarrie Hub).** This is carried out through Kalgoorlie Nickel Pty Ltd (KNPL), the incorporated joint venture that manages the DFS. The DFS is fully funded by the Japanese consortium. Ardea provides technical and commercial input, corporate management and the asset base. 2. **Resource stewardship of the wider KNP (Kalpini Hub and other deposits).** The Kalpini Hub (270Mt at 0.76% Ni, 0.05% Co, per the Diggers & Dealers presentation, August 2026) remains 100% Ardea and is not subject to the consortium's earn-in. 3. **Exploration.** Ardea explores for nickel sulphide (for example at Kalpini) and for critical minerals including scandium, rare earth elements, lithium-caesium-rubidium, PGEs and gold across its Eastern Goldfields tenure. 4. **By-product optionality.** In mid-2026 Ardea began a sole-funded scoping study on recovering scandium and other critical minerals from the planned plant's barren-liquor waste stream (DFS Update, 3 June 2026). ### Business model and revenue model **Current revenue model:** None from product sales. Reported "other revenue/income" (A$3.68M in FY2025 per StockAnalysis) consists of non-operating items such as R&D tax incentive refunds (for example the A$1.1M R&D rebate announced 13 June 2024), interest income, and, most likely, cost recoveries or management charges connected with the KNPL joint venture. The precise composition should be checked against the FY2026 Annual Report notes. **Prospective model:** A miner-processor selling an intermediate nickel-cobalt product. The 2023 PFS assumed mixed hydroxide precipitate (MHP). The DFS has since switched the product to mixed sulphide precipitate (MSP), sold into battery-precursor and nickel-refining supply chains. Sumitomo Metal Mining, a leading Japanese nickel refiner and cathode-material producer, is the natural offtaker; marketing terms remain subject to DFS and FID. **Mix:** Product 0% / service 0% / subscription 0% / licensing 0% (pre-revenue). ### Value-chain position Ardea sits at the upstream end: resource ownership, mine planning and hydrometallurgical processing to an intermediate product (MSP). Downstream refining to nickel sulphate, precursor (pCAM) and cathode (CAM) manufacture is outside Ardea's scope and inside the core competence of its partner SMM. ### Customer types and end-markets **Prospective customers:** Nickel refiners and battery-materials producers, primarily the consortium members, plus Western OEM supply chains seeking non-Chinese, non-Indonesian, "free-trade-aligned" nickel and cobalt. US interest is evidenced by a letter of interest from US EXIM (Feb 2026). **End-markets:** Lithium-ion batteries (EV and stationary storage), stainless steel and alloys (nickel); batteries and superalloys (cobalt); aerospace aluminium-scandium alloys and solid-oxide fuel cells (scandium, prospective). ### Company's own description (paraphrased from FY2025/FY2026 reports and 2026 releases) Ardea describes itself as an ASX-listed nickel development company in joint venture with Sumitomo Metal Mining and Mitsubishi Corporation, focused on developing the KNP Goongarrie Hub as a low-cost, multi-decade nickel-cobalt producer built to modern ESG standards. It adds that it explores for nickel sulphide and critical minerals, including scandium and rare earths, across the broader KNP area. Earlier reports used the label "battery and critical minerals company". ### Independent characterisation Ardea is best understood as a project-equity vehicle: a listed holding company whose principal asset is a 65% interest in an incorporated JV owning a very large, low-grade-but-shallow laterite resource, plus a 100% interest in a second large laterite hub. Three things determine its economics: 1. Whether the DFS confirms a financeable, internationally competitive HPAL/leach project at a time when Indonesian HPAL supply has structurally lowered nickel prices. 2. How Ardea funds its share of a multi-billion-dollar capex. PFS capex was A$3.12B in 2023 dollars, and the company has acknowledged industry-wide cost escalation since. 3. Whether government-backed critical-minerals financing (Export Finance Australia, US EXIM, Japanese agencies) can bridge a gap that private capital alone has been reluctant to fill in Western nickel.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2016
West Perth, Australia
Arafura

Arafura Resources Limited

Premium
Information Technology

Arafura Rare Earths is a pre-revenue, single-asset critical minerals developer whose entire value rests on the Nolans Rare Earths Project in Australia's Northern Territory, which reached a final investment decision (FID) on 21 May 2026 and began construction in September 2026. Nolans is designed as a fully integrated, single-site "ore-to-oxide" operation: mining, beneficiation, acid leaching, rare earth separation and phosphoric acid production all occur at one location, producing an average of 4,440 tonnes per annum of separated neodymium-praseodymium (NdPr) oxide over a 38-year mine life, together with a mixed middle/heavy rare earth oxide containing dysprosium and terbium, and phosphoric acid as a by-product credit. The project is backed by an unusually broad sovereign coalition—export credit agencies from five countries, three Australian government financiers, Germany's raw materials fund, and the US-Australia Critical Minerals Framework—and is positioned as one of very few non-Chinese sources of separated magnet rare earth oxides scheduled to enter production around end-2029. --- ### What the company does Arafura is a mineral development company. It currently generates no operating revenue; its income consists of interest on cash and term deposits. Its activities are: (i) constructing the Nolans Project; (ii) securing and administering project finance (senior debt, cost-overrun facilities, convertible notes, strategic equity); (iii) marketing future production under long-term offtake agreements; and (iv) holding exploration tenure in the surrounding Aileron-Reynolds region (six granted exploration licences covering ~1,240 km², per company description reproduced by Investing.com). ### Company self-description (paraphrased from latest disclosures) In its FY2026 reporting and investor materials, Arafura describes itself as developing Australia's first fully integrated ore-to-oxide rare earths operation, producing "radiation-free" NdPr oxide for the permanent magnet supply chain serving electric vehicles, wind turbines and other high-technology applications. It emphasises that because separation to oxide occurs on site, radionuclides are removed before product leaves Nolans, giving customers in any jurisdiction direct access without reliance on Chinese intermediate processing (FY2026 results call, 3 Sep 2026). ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue model (future) | 100% product sales: NdPr oxide (primary value driver), mixed middle/heavy rare earth (SEG/HRE) oxide including DyTb, and phosphoric acid by-product | | Product vs service vs subscription vs licensing | Product: ~100%. Service, subscription, licensing: nil | | Pricing basis | Long-term offtake contracts. Earlier contracts (e.g., Traxys Europe, March 2025) referenced China ex-works NdPr prices; 2026 contracts (Traxys North America; Indian counterparty; extended wind OEM contract) reference independent global "seaborne" price indices (Benchmark Mineral Intelligence, S&P Global Platts) | | Customer types | Automotive OEMs (Hyundai Motor, Kia), wind turbine OEM (Siemens Gamesa, extended in Sept 2026 as an unnamed "global wind turbine OEM"), metals traders (Traxys Europe, Traxys North America), an Indian government-backed magnet programme participant, and potentially the Australian Government's Critical Minerals Strategic Reserve | | End-markets | Rare earth permanent magnets (NdFeB) for EV traction motors, wind turbine generators, robotics/humanoids, industrial motors, consumer electronics, defence | | Value chain position | Upstream-to-midstream: mine → concentrate → chemical processing → separated oxide. Downstream of Arafura: metallisation, alloying, magnet manufacturing, component and OEM assembly | ### Independent characterisation Arafura is best characterised as a de-risked but unproven construction-stage project company. The defining strategic choice—integrating separation at the mine site rather than selling a concentrate or mixed carbonate—raised capital intensity (development cost ~US$1.6B; total funding requirement ~US$1.9B including cost-overrun and liquidity facilities) but enabled the company to attract sovereign financing explicitly targeted at non-Chinese supply chain capability. The phosphate-hosted ore body allows on-site generation of phosphoric acid, which is used in the process and sold as a by-product credit; management claims this moves Nolans from mid-cost-curve to the bottom quartile (FY2026 results call). The principal analytical issues are execution (37-month remote-site build), ramp-up risk inherent in hydrometallurgical rare earth plants, and NdPr pricing, which until 2025 was dominated by opaque Chinese domestic benchmarks.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1997
Perth, Australia
Apollo

Apollo Minerals Limited

Premium
Information Technology

Apollo Minerals is a Perth-headquartered, dual-listed (ASX/Euronext Growth Paris) exploration company. Since January 2026 its strategy has centred on reactivating the Couflens tungsten-gold project in the French Pyrenees. Couflens hosts the historic Salau mine, which operated from 1971 to 1986 and was among the world's highest-grade tungsten operations, producing roughly 930,000 tonnes of ore at about 1.5% WO₃. In late 2025 the company won a seven-year legal battle when France's Conseil d'État restored the 42 km² exploration permit. With China dominating tungsten supply and the EU classifying tungsten as a critical raw material, Apollo presents itself as a rare European-domiciled route to high-grade primary tungsten supply. It retains secondary exposure to the province-scale Kroussou zinc-lead project and the Salanie gold project in Gabon, plus historical copper ground in Serbia. The company has no revenue, holds no debt, and funds itself entirely through equity markets. Its value depends on permitting outcomes and drilling results. --- ### What the company does Apollo Minerals acquires, explores and evaluates mineral permits and mining assets. Euronext describes its business in exactly these terms: exploration and development of mineral deposits, with major tungsten, gold and zinc-lead projects in France and Gabon (Euronext press release, 30 June 2026). The company produces nothing and sells nothing. Its "product" is the discovery and de-risking of mineral deposits. That value can eventually be realised in three ways: development into a producing mine, sale or joint venture of an asset, or a corporate transaction. ### The company's own description **FY2023 Annual Report (pre-Couflens reinstatement):** Apollo described itself as a "responsible mining company" focused on three core projects: the Kroussou Zinc-Lead Project and the Salanie (Salane) Gold Project in Gabon, and the newly acquired Belgrade Copper Project in Serbia. **2026 (post-reinstatement):** Company materials, including the February 2026 Corporate Presentation, the June 2026 Euronext Information Document and the quarterly reports, lead with the Couflens High-Grade Tungsten-Gold Project. They frame it as the opportunity to reactivate the high-grade Salau mine, combined with significant gold potential. Gabon is presented as secondary exposure: two active exploration licences covering a combined 2,363.5 km² in western Gabon (Euronext Information Document as summarised by Discovery Alert, Jun 2026). **Segment definition:** The annual report treats the company as a single operating segment, "exploration for mineral resources," with geographic activities in Gabon, Australia and Serbia (Morningstar profile, citing FY2025 Annual Report). From 2026, France has become the dominant area of activity. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | None. Pre-revenue explorer. Recorded "revenue" is limited to interest and other income: A$61.4k in FY2025 and A$29.5k in FY2021 (TipRanks income statement). | | Product / service / subscription / licensing mix | Not applicable. 100% exploration expenditure. | | Funding model | Equity placements, entitlement offers and option exercises. Investing inflows come from occasional asset or investment disposals. | | Value-creation levers | (1) Permitting and title security; (2) historical data validation; (3) drilling to confirm and extend mineralisation; (4) JORC Mineral Resource estimation; (5) studies (scoping, PFS, DFS); (6) strategic partnering, offtake or sale. | | Value chain position | Upstream: greenfield/brownfield exploration. Couflens is technically a brownfield redevelopment of a past-producing mine. | | Potential future customers | Couflens: tungsten concentrate (scheelite) buyers such as APT converters, cemented-carbide and tooling producers, and defence and aerospace supply chains. Kroussou: zinc and lead concentrate smelters. Salanie: gold refiners. | | End-markets (if developed) | Tungsten: cemented carbides for mining, construction and machining tools, defence (munitions and armour), aerospace, electronics, automotive. Zinc: galvanising for steel. Lead: batteries. Gold: investment and jewellery. | ### Independent characterisation Apollo is best understood as a jurisdiction-arbitrage critical-minerals explorer. Its investment case rests less on new geological discovery than on regaining legal access to a historically proven, very high-grade tungsten deposit inside the European Union, at a moment of acute Western supply-security concern. The geological risk at Salau is arguably lower than at a typical greenfield project, given 15 years of production records, about 950 historical diamond holes and about 2,700 underground face samples (ASX release, 9 Apr 2026). The social licence and legal risk is exceptionally high. Organised local opposition, including the Couflens commune and environmental associations, has litigated the permit continuously since 2016 (Conseil d'État decision no. 493561, 24 Nov 2025). The Gabon assets are optionality held at low carrying cost. Serbia appears to have been de-emphasised: Euronext's own 2026 description refers only to France and Gabon, while the Jeantet deal note still references Serbia.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2007
Perth, Australia
Apollo

Apollo Consolidated Limited

Premium
Information Technology

Apollo Consolidated was a Perth-based gold explorer. It turned a portfolio of West African and Western Australian grassroots interests into one of the more contested gold development assets in the Eastern Goldfields. Its value rested on the Lake Rebecca gold project, about 150 km east-northeast of Kalgoorlie in the Norseman–Wiluna greenstone belt. There, Apollo defined a JORC resource of 29.1 Mt at 1.2 g/t for about 1.1 Moz, about three-quarters in the Indicated category. Apollo was unusual among juniors because it funded much of its exploration without dilution. It monetised non-core Côte d'Ivoire assets, including a A$20M sale of its 1.2% NSR royalty over the Seguela project and a US$4.5M sale of its residual interests in the Liberty and Bagoe projects. In October–November 2021, a bidding contest between Ramelius Resources and Gold Road Resources ended with Ramelius paying about A$181M. The asset now anchors Ramelius' planned second processing hub, Rebecca-Roe. --- **What the company did.** Apollo was a mineral exploration and project-development company. It did not mine, process or sell gold. Its business model was the classic junior-explorer model: acquire prospective ground, use equity and asset-sale proceeds to fund drilling, grow a JORC-compliant resource, advance it toward studies and an eventual development decision, and create value either by developing it or selling it to a producer. Apollo took the second path. **Revenue model.** Apollo had no product, service, subscription or licensing revenue. Its income came from: - interest on cash balances, - one-off gains on asset sales (the Seguela royalty and the Côte d'Ivoire minority interests), and - historically, the receipt of listed shares (Exore Resources) as consideration for vending tenements, which it distributed in specie to its shareholders. **Value-chain position.** Upstream: greenfield and brownfield exploration and resource definition. Apollo sat before the development, mining, processing and refining stages. **Customer types and end markets.** Apollo had no direct customers. Its "buyers" were the capital markets (equity investors), royalty companies (Gold Royalty Corp.), private equity (Ibaera Capital), joint-venture partners (Exore Resources, IGO Ltd) and ultimately mid-tier gold producers acquiring development pipelines (Ramelius, Gold Road). The underlying end market is gold, which is used in investment, central-bank reserves, jewellery and technology. **Company's own characterisation.** Apollo described itself in its later public materials as a Perth-based gold explorer focused on the Eastern Goldfields of Western Australia, led by the Lake Rebecca project. It noted the high-grade Jennifer Lode discovery and the surrounding bulk mineralisation. It also listed secondary greenfield gold projects at Yindi and Larkin, the Louisa nickel-copper sulphide project in the Kimberley (farmed out to IGO), and, until early 2021, its NSR royalty over Roxgold's Seguela project in Côte d'Ivoire (paraphrased from Argonaut's transaction summary of Apollo). **Independent characterisation.** Apollo is best understood as a "discovery-to-sale" junior that made two good capital-allocation decisions: 1. **It pivoted early.** It switched its focus from Côte d'Ivoire to Western Australia after mid-2017 diamond drilling at Rebecca returned high-grade intercepts. 2. **It funded the pivot with non-dilutive money.** It monetised its African legacy assets rather than relying only on placements. The geology changed the investment case. Rebecca began as a high-grade discovery but proved to be a lower-grade, bulk-tonnage system as drilling continued (Stockhead, Oct 2021). This favoured a well-capitalised producer with processing and development capability over a stand-alone junior. That logic drove the 2021 takeover contest.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2002
Perth, Australia
Dexus

Dexus Industria REIT

Premium
Information Technology

Dexus Industria REIT is a small-to-mid-cap, externally managed Australian REIT that, as of FY26, is a pure-play industrial landlord following the divestment of Brisbane Technology Park, its last non-industrial asset. It owns interests in 90 properties valued at A$1.5 billion, with roughly 77% of value in land-constrained urban infill markets and a substantial 33.3% stake in the ASCEND Industrial Estate at Jandakot Airport, Perth — the fund's principal development engine, with a A$217 million pipeline. Its value proposition rests on three pillars articulated by management: a ~6.8% distribution yield (as at 7 August 2026), embedded growth from fixed/CPI-linked reviews and positive re-leasing spreads, and a deep discount to NTA (~29% at results; ~33% at today's price). DXI's differentiators are access to Dexus's ~A$11 billion industrial platform and low gearing (31.2%); its key handicaps are sub-scale market capitalisation, external-management related-party dynamics and earnings sensitivity to interest costs. --- **Company's own description (paraphrased from the FY26 Release "About" section).** DXI describes itself as a listed Australian REIT invested in high-quality industrial warehouses located across the major Australian cities, intended to provide sustainable income and capital growth to securityholders over the long term, operating within a 30–40% target gearing range, governed by a majority-independent board and managed by Dexus, a fully integrated real asset group with more than four decades of experience. Its stated investment proposition is to generate strong risk-adjusted returns for investors seeking listed industrial real estate exposure (HY26 financial report). **Independent characterisation.** DXI is a rent-collecting vehicle whose economics are driven by (i) contracted rental escalations (~87% of income subject to fixed or CPI-linked reviews, mostly ≥3%), (ii) mark-to-market of rents at expiry (21.4% re-leasing spread in FY26), (iii) occupancy (98.8%), (iv) development profits at Jandakot (FY26 completions at a 7.0% yield on cost versus a 5.91% portfolio cap rate), offset by (v) interest costs (average cost of debt rose from 4.3% to 4.9% in FY26) and (vi) management fees paid to Dexus. Earnings are reported as Funds From Operations (FFO) under the Property Council of Australia definition.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2013
Sydney, Australia
APN

APN Convenience Retail REIT

Premium
Information Technology

Dexus Convenience Retail REIT is a small-capitalisation, single-sector Australian REIT that owns the land and buildings underneath fuel and convenience retail sites, leasing them on long-dated, largely triple- or double-net terms to large-cap fuel and convenience operators including Chevron (Caltex), Viva Energy, Ampol, 7-Eleven, BP, United and Mobil. Its 91-asset, A$779m portfolio is weighted 86% to metropolitan and highway locations and 77% to the eastern seaboard by value, with Queensland the dominant state. The investment case is income-led: 73% of income escalates at fixed rates of roughly 3.1% a year, 95% of income comes from major national or international tenants, and no significant lease expiries occur before FY2032. Managed externally by Dexus, DXC differentiates from the larger Waypoint REIT through tenant diversification and an active recycling-into-development strategy anchored by quick-service-restaurant (QSR) co-tenancies, while trading at a persistent c.30% discount to NTA and a c.7.5-7.8% distribution yield. --- **What the company does.** DXC is a passive-to-active landlord of service station and convenience retail real estate. It owns freehold sites (land, buildings and in most cases forecourt improvements) and leases them to operators who run the fuel, convenience store and food businesses. DXC does not sell fuel, operate stores, or take retail margin risk directly; its revenue is contractual rent plus recoveries of outgoings. **Company's own description.** In its HY26 Operating and Financial Review, DXC describes itself as taking an active and disciplined approach to investing in strategically located assets to produce a defensive income stream from a property portfolio, assessing opportunities across commercial real estate with a focus on convenience retail and other non-discretionary assets, including fuel service stations. The fund articulates four delivery pillars: generating defensive income with contracted rental growth; taking an active approach to portfolio management; maintaining a prudent capital structure; and leveraging Dexus's real asset capabilities (HY26 Interim Report, Feb 2026). The FY26 results presentation reframes this into three priorities: defensive and growing income, prudent capital structure, and active portfolio management. **Business model.** The economic engine is the spread between the portfolio capitalisation rate (6.18% at June 2026) and the cost of debt (4.8% weighted average in FY26), applied to a moderately geared balance sheet (30.6% gearing), with growth delivered by contracted rent escalators (average review of 3.3% in FY26) and periodic capital recycling. Lease structures are predominantly double-net and triple-net, so tenants carry most outgoings, repairs and environmental liabilities; DXC retains capital and structural repair obligations, which under some leases can extend to replacing underground fuel or LPG tanks (HY26 Interim Report, Note 8). **Revenue model mix.** 100% property leasing. In HY26, property revenue of A$27.4m comprised rental income A$24.4m (89%), outgoings and direct recoveries A$2.5m (9%), services revenue A$0.9m (3%) and negative incentive amortisation of A$0.3m (HY26 Interim Report, Note 2). There is no product, subscription or licensing revenue. **Value chain position.** DXC sits at the real-estate capital layer of the fuel and convenience value chain: upstream of it are refiners and importers (Ampol, Viva, Chevron/ENEOS, BP, ExxonMobil-supplied Mobil); alongside it are operators and franchisees; downstream are motorists and convenience shoppers. Operators increasingly use sale-and-leaseback to recycle capital out of property, which has historically been a source of DXC's acquisition pipeline, while DXC also funds new developments through "fund-through" structures. **Customer types.** Major national and international fuel and convenience operators provide 95% of income. By income at FY26: Chevron 25%, Viva Energy 22%, Ampol 14%, 7-Eleven 13%, BP 4%, United 4%, Mobil 4%, and convenience retail and other non-fuel tenants 14% (FY26 results presentation, slide 9). The fund reports 62 tenant operators (up from 18 at IPO) and 69 specialty retail tenancies, with QSR brands including McDonald's, KFC, Hungry Jack's and Guzman y Gomez. **End-markets served.** Australian road fuel retailing (petrol, diesel, LPG), convenience retail, and roadside food service. The underlying demand driver is vehicle traffic: the portfolio has an estimated 1.9 million vehicles passing its sites daily and 2.6 million people within a 3km radius (FY26 presentation, citing GapMaps and internal traffic data). **Independent characterisation.** DXC is best understood as a long-WALE, bond-like real estate vehicle with embedded optionality from high-value zoning (87% of value zoned to commercial, industrial, residential and mixed uses) and a modest development overlay. Its key sensitivities are interest rates (via both cost of debt and cap rates), tenant concentration in four groups (74% of income), and the long-dated question of fuel demand under electrification. Being externally managed, it pays a base fee of 0.65% of gross asset value, which is a structural drag relative to internally managed peers.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2017
Sydney, Australia
APCMinerals

APC Minerals Limited

Premium
Information Technology

APC Minerals Limited is a Perth-based, nano-cap mineral exploration company. It has emerged from a failed attempt to build Australia's first large-scale, field-evaporated sulphate of potash (SOP) operation at Lake Wells in Western Australia's north-Eastern Goldfields. After that project lost viability in 2023, the company went through voluntary administration and a creditor-supported Deed of Company Arrangement. It was recapitalised in 2024, consolidated its shares 40:1, and renamed itself APC Minerals in late 2024. The company now holds two 100%-owned early-stage exploration assets: **Laverton Downs Gold Project:** three granted licences immediately north of Laverton, straddling the Lancefield and Rosemont-Barnicoat gold trends. **Nexus Project:** three licences covering about 636 km² in the West Arunta, a frontier niobium/rare-earth province. APC has no revenue, no resources and no reserves, and around A$1M of cash. Its value proposition is discovery optionality, and it depends on repeated equity raisings. --- ### Company's own description In its interim financial report for the half-year ended 31 December 2025, the company says its principal activity is mineral exploration in the North-Eastern Goldfields and West Arunta regions of Western Australia. Note 3 of that report identifies a single reportable segment: exploration activities undertaken in Australia. This covers work to determine and assess whether commercially economic reserves exist on the company's mineral assets. The standard "About APC" boilerplate in the 2026 quarterly reports describes the two assets as follows: **Laverton Downs Project (LDP):** about 15 km north of Laverton, prospective for gold, nickel and other base-metal sulphides, and located in the gold-bearing Lancefield sequence. **Nexus Project:** about 1,000 km east-southeast of Port Hedland. It is an early-stage opportunity surrounded by significant and emerging rare earth and critical-mineral deposits, in a region the company calls WA's most exciting exploration frontier, with sedimentary, IOCG, SEDEX and carbonatite-hosted potential. ### Independent characterisation APC is a pre-resource, pre-revenue junior explorer. Its business model is the classic ASX "prospect generator / discovery" model: 1. Acquire or retain tenure cheaply. 2. Spend modest equity-funded sums on geophysics, geochemistry and drilling. 3. Try to create value through a discovery announcement, a JORC Mineral Resource, or a farm-out, joint venture or sale of the project to a better-capitalised party. Characterising the company in terms of revenue model is close to meaningless: - There is no product, service, subscription or licensing revenue. - Income consists only of interest, a small amount of corporate sponsorship received by the now-closed Laverton Training Centre (A$21,209 received in H1 FY2026; A$60,000 in H1 FY2025), and one-off asset disposals. - The value chain position is the very first upstream stage: greenfield and brownfield exploration. - Potential end-markets are speculative. If discoveries were made, gold would go to refiners and central bank/investor demand, and niobium/REE to steel micro-alloying, superconducting magnets and permanent magnets. These would be realised only through a sale or development years in the future. ### Legacy business (context) From 2016 to 2023, as Australian Potash Limited, the company was a would-be SOP fertiliser producer. Its flagship was the Lake Wells SOP Project, which used solar evaporation of hypersaline brine. Key milestones included: - Offtake agreements, including a binding term sheet with Redox Pty Ltd for 20,000 tpa of its "K-Brite" premium SOP. - A reported A$140M Northern Australia Infrastructure Facility (NAIF) funding approval covering more than two-thirds of development costs. - A 2022 expansion study raising planned output from 170,000 tpa to 205,000 tpa. That study reported post-tax NPV rising from A$614M to A$1.01B and capex rising 39% from A$292M to A$408M (Mining Weekly, 28 Feb 2023). The project failed to obtain full funding as sentiment towards WA solar-evaporation potash collapsed after the failures of Salt Lake Potash (2021) and Kalium Lakes (2023). Leases were surrendered in August 2023, and administrators were appointed in December 2023 (Mining Weekly, 8 Dec 2023).

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2011
Perth, Australia
Antilles

Antilles Gold Limited

Premium
Information Technology

Antilles Gold is an Australian-listed, pre-production mining developer whose entire economic interest is a 50% shareholding — held via Cayman Islands subsidiary Antilles Gold Inc (AGI) — in Minera La Victoria S.A. (MLV), a joint venture with Gold Caribbean Mining S.A., a subsidiary of Cuba's state mining company GeoMinera S.A. MLV holds the Nueva Sabana gold-copper oxide project in central Cuba, where construction began in December 2025, and the La Demajagua gold-silver-antimony deposit on the Isle of Youth, plus porphyry copper exploration ground at El Pilar, San Nicolás and La Cristina. The company emerged from the PanTerra Gold/Las Lagunas tailings business in the Dominican Republic, which closed in 2019. Its investment case rests on first-mover access to underexplored Cuban mineral provinces. That case was severely impaired on 4 June 2026, when the US Treasury designated MLV a Specially Designated National. Construction is now suspended pending a proposed US-ownership restructuring of AGI. --- ### What the company does Antilles Gold is a holding and project-sponsor company. It does not itself own a mine. Its operating economics flow through three channels: 1. **Equity interest:** a 50% equity interest in MLV, accounted for under the equity method. The carrying value was US$14.99M at 31 Dec 2025 (FY2025 AR, Note 19). 2. **Shareholder loans:** loans from AGI to MLV at 12% p.a. compounding monthly, with interest capitalised until Nueva Sabana is cash-positive. The balance was US$2.00M at 31 Dec 2025 (FY2025 AR, Note 17). A further ~US$2.0M of loan advances were made in Q2 2026 (June 2026 quarterly). 3. **Planned trading role:** management stated in the FY2024 Annual Report that AGI was intended to act as intermediary between the mine and concentrate purchasers. Separately, the company has disclosed an option to purchase antimony cathodes from La Demajagua at prevailing Chinese prices for downstream processing outside Cuba (13 Nov 2025 ASX release). ### Business model and revenue model | Revenue type | Current mix | Prospective mix (management intent) | |---|---|---| | Product sales | 0% | Indirect — via 50% of MLV dividends from concentrate sales | | Services | 0% | AGI was to supervise and administer the Xinhai EPC contract (Sept 2025 MOU) | | Subscription / licensing | 0% | Historically, a 1.5% technology fee on La Demajagua sales for the Albion process was contemplated; abandoned when the Albion asset was impaired in FY2022 | | Interest income | 100% of reported revenue (FY2025) | Continues on shareholder loans | | Trading / marketing margin | 0% | Potential concentrate intermediary and antimony offtake role | The company is pre-revenue in operating terms. Its revenue line in FY2025 (US$187,743) consisted entirely of bank interest and interest on the loan to MLV. FY2025 "other income" of US$2.17M was an interim liquidation distribution from the former Dominican subsidiary, EnviroGold (Las Lagunas) Limited (FY2025 AR, Notes 4–5). ### Value-chain position Upstream: exploration, resource definition, feasibility, and mine development (through the JV). MLV's planned products are intermediate concentrates — gold concentrate and copper-gold concentrate from Nueva Sabana, and a gold-arsenopyrite concentrate plus antimony cathode or concentrate from La Demajagua — for sale to international traders and smelters. Binding offtake agreements for 100% of Nueva Sabana concentrates were signed in May 2025 with an unnamed major global commodities trader (roic.ai summary of ASX disclosures). ### Customers and end-markets **Direct customers (prospective):** international commodity traders for concentrates; potentially Chinese antimony processors or smelters. **End-markets:** gold (investment and jewellery), copper (electrification and construction), silver, and antimony (flame retardants, lead-acid batteries, defence and strategic alloys). Antimony has acquired critical-mineral status in the US and EU. ### The company's own description The FY2025 Annual Report describes Antilles Gold as developing two mines in Cuba through a 50:50 joint venture with a subsidiary of the Cuban government's mining company, GeoMinera SA, to produce gold, copper, silver and antimony. It notes that MLV also holds exploration concessions covering several identified porphyry copper deposits. ### Independent characterisation Antilles Gold is best understood as a single-jurisdiction, sanctions-exposed, minority-financier vehicle into Cuban state-partnered mining. Its distinguishing feature is not geology — the deposits are modest — but political access to a closed mining jurisdiction. Its principal liabilities are: - the absence of Western project finance; - the absence of D&O insurance since February 2019; - dependence on Chinese contractors and capital (Xinhai Mining); - since June 2026, a direct US sanctions designation of the operating JV. The company is effectively an option on US–Cuba sanctions policy and on the GEM-led restructuring.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1984
Bowral, Australia
Hartshead

Hartshead Resources NL

Premium
Information Technology

Hartshead Resources NL, formerly Ansila Energy NL and before that Pura Vida Energy NL, is a Perth-incorporated, London-operated upstream gas development company whose value is concentrated almost entirely in a 40% (reducing to 35%) non-operated-in-transition interest in UK Seaward Production Licence P2607 in the Southern Gas Basin of the North Sea. The licence holds the undeveloped Anning and Somerville gas fields (Phase I: 52.4 MMboe gross 2P reserves per ERCE, June 2022), the Hodgkin and Lovelace contingent resources (Phase II) and an exploration inventory (Phase III), alongside six further licences awarded in the UK's 33rd round. Having farmed out 60% to RockRose Energy (Viaro Energy group) in 2023 and wrestled with UK fiscal changes, export-route redesign and permitting delays, the company accepted an all-cash takeover by natural-resources partnership ACAM LP at A$0.014 per share, completed in June 2026. It is now a private, pre-production asset vehicle with no revenue from hydrocarbon sales. --- **Company's own description (latest report, H1 FY2026 interim report, 16 March 2026).** The company describes itself as an Australian-listed oil and gas exploration and development company whose principal interest is P2607 in the UK southern gas basin, with a stated strategy of extracting value from its assets and, over time, building a European-focused gas development company. Management determined that the group has one reportable segment: an interest to develop and explore for gas fields in the UK North Sea. **Independent characterisation.** Hartshead is a single-asset-centric, pre-FID gas developer. It has never produced hydrocarbons and has no product sales revenue. Its income has consisted of: **Operator fees:** earned under the P2607 Joint Operating Agreement while HHR UK acted as operator, reflecting recovery of costs from the farminee (A$1.21m in H1 FY2026; A$0.80m in H1 FY2025). **Interest and investment income:** on cash, Australian government bonds and listed bank convertible notes (interest A$0.28m in H1 FY2026). **One-off farm-out gains:** (FY2023 reported a net profit of approx. A$1.5m per aggregator data, coinciding with the RockRose farm-out completion). **Business model.** The model is the classic junior E&P "acquire–de-risk–farm-out–monetise" cycle: secure acreage cheaply through licensing rounds or corporate acquisition, add value through subsurface work and development planning, then farm down equity in exchange for cash and carried development spending, and ultimately either reach production or sell the company. The 2026 sale to ACAM represents the final monetisation step for public shareholders. **Revenue model mix.** Product: 0%. Service (operator fees): the large majority of operating "other income". Subscription/licensing: 0%. Investment income: residual. **Value-chain position.** Upstream only — exploration, appraisal and development planning. The planned Phase I value chain would have run from two normally unmanned platforms (six wells) via pipeline to the Saturn Banks pipeline system (CalEnergy Resources) and on to the Perenco-operated Bacton gas terminal for processing before entering the UK National Transmission System. **Customer types / end-markets.** No customers to date. Prospective end-market: UK wholesale natural gas (NBP-linked sales) for power generation, industry and domestic heating. The farm-out disclosures referred to possible pre-sale of net gas as a financing option.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2011
Northbridge, Australia
Warriedar

Warriedar Resources Limited

Premium
Information Technology

Warriedar Resources Limited — the entity formerly listed as Anova Metals — evolved from a Nevada-focused gold developer into a Western Australian gold-antimony explorer whose resource growth made it an acquisition target. Under managing director Amanda Buckingham, the company consolidated three Murchison-region project areas in 2022–23 (Warriedar, Golden Dragon/Golden Range and Fields Find), then used focused deep drilling to more than double the Ricciardo deposit and, in May 2025, define what it described as Australia's largest open-pit antimony resource. By mid-2025 group resources stood at roughly 2.3Moz gold equivalent across WA, alongside a ~1Moz permitted gold resource at Big Springs, Nevada. That resource base, located about 90km north of Capricorn Metals' Mt Gibson project, led Capricorn to acquire the company by scheme in November 2025. Warriedar now functions as Capricorn's holding vehicle for Golden Range, which Capricorn is studying as a potential second Mt Gibson processing hub under its "Range 500" production aspiration. --- **What the company does.** Throughout its listed life the company was a mineral exploration and project-development business. It did not operate a mine on a continuous basis in its final years and generated no material sales revenue after the Linden/Second Fortune divestment in 2020. Value creation came from acquiring under-explored ground, delineating JORC (2012) Mineral Resources through drilling, and monetising them through divestment or corporate transaction. **Business model.** A classic junior-explorer model applied: equity capital (placements, share purchase plans, option exercises) funded drilling; drilling converted into resource ounces; resource ounces drove market value; and value was crystallised by sale of the company to a producer. There was no product, service, subscription or licensing revenue mix. The only historical operating revenue identified was gold sales from the Second Fortune mine (Linden project) under the Anova name, which aggregator data put at about 3.7m for FY2018 and 2.8m for FY2019 (Barchart; labelled as thousands, currency labelling inconsistent with the AUD-denominated accounts), falling to nil from FY2020. **Value-chain position.** Upstream explorer/developer. The company held mining leases and a care-and-maintenance processing plant at Golden Range, so it owned some mid-stream infrastructure (an 800ktpa carbon-in-leach plant, ROM pad, tailings facility, haul road and grid connection, per company project descriptions summarised by roic.ai), but the plant was not operating during the Warriedar period. **Customer types and end-markets.** As an explorer it had no customers. Its prospective end-markets were (i) gold, sold into the global bullion market via refiners such as the Perth Mint in WA practice, and (ii) antimony, a critical mineral used in flame retardants, lead-acid batteries, munitions and semiconductors, then experiencing what the company and market commentary described as a supply squeeze with sharply higher prices. **Company self-description (latest standalone disclosures).** Warriedar described itself in 2025 as a gold and antimony exploration company focused on rapidly building resource inventory through modern exploration, with two operating segments: Western Australia and the United States (Morningstar segment summary of the annual report). In its 1 May 2025 resource release it framed the goal as growing gold resources along the 25km "Golden Corridor" in parallel with advancing antimony. **Independent characterisation.** Warriedar was a well-executed "resource growth" junior whose key insight was that historical open pits at Golden Range had been mined only to shallow depth (average depth under 60m, per Stockhead, Feb 2023) and almost never drilled below about 100m. Targeted deep drilling at Ricciardo doubled the gold resource in 2024, and a re-logging of core revealed stibnite-hosted antimony that added a critical-minerals dimension in 2025. The company never solved the funding and permitting path to production on its own; instead, the obvious strategic buyer — Capricorn, operating 90km to the south — paid a premium to consolidate the district. Today, the "business" is effectively an asset-holding subsidiary inside Capricorn's Mt Gibson hub strategy.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2010
West Perth, Australia
Anglo

Anglo Australian Resources NL

Premium
Information Technology

Astral Resources NL is a Perth-based, pre-production gold developer. It is consolidating a district-scale, open-pit, free-milling gold hub about 70 km south of Kalgoorlie in Western Australia's Eastern Goldfields. Its flagship Mandilla Project combines three 100%-owned assets: the Mandilla Gold Project, anchored by the 1.39 Moz Theia deposit; the Feysville Gold Project near the KCGM Super Pit; and the Spargoville Gold Project, acquired through the 2025 takeover of Maximus Resources. Group Mineral Resources are 61.6 Mt at 1.0 g/t Au for 2.07 Moz, and Ore Reserves are 1.08 Moz. The June 2025 Pre-Feasibility Study outlined a 2.75 Mtpa standalone operation producing about 95 kozpa for 12 years, with a pre-tax NPV8 of A$1.4 billion at A$4,250/oz. The company is funded with about A$65 million in cash and no debt. The Definitive Feasibility Study is due in the March quarter of 2027, followed by a Final Investment Decision and an early-cash-flow joint venture at Think Big. --- **What the company does.** Astral explores for and evaluates gold deposits in Western Australia and is moving toward development. It owns no operating mine and earns no sales revenue. Its reported "revenue from continuing operations" (A$1.86M in FY2026) is almost entirely interest on cash deposits. Appendix 5B for FY2026 shows A$1.088M of interest received. The business model is the standard ASX junior-developer model: raise equity, convert drilling into JORC-compliant Mineral Resources and Ore Reserves, complete feasibility studies, then either (a) fund and build a mine with a debt/equity package, (b) monetise assets through joint ventures or toll-treatment arrangements, or (c) be acquired by a larger producer. **Company's own description (June 2026 Quarterly Report, "About Astral Resources", paraphrased).** Astral describes itself as a gold-focused exploration company growing and developing its flagship Mandilla Project, which comprises the Mandilla, Feysville and Spargoville Gold Projects. Mandilla is about 70 km south of Kalgoorlie. Feysville is about 14 km south of the KCGM Super Pit. Spargoville covers about 144 km² of tenure that is mostly contiguous with Mandilla. The company also holds gold rights at Carnilya Hill in the WA Goldfields. **Revenue model mix.** **Value-chain position.** Astral sits at the upstream end of the gold chain: exploration, resource definition and feasibility. The planned Mandilla operation would integrate open-pit mining (by contractor, per PFS assumptions) and on-site carbon-in-leach (CIL) processing through a 2.75 Mtpa plant, producing gold doré for sale to a refiner such as the Perth Mint. The Think Big JV would be a different model. The mining-services partner MMS would fund and run development and recoup its costs before profits are shared. This route gives early cash flow without Astral building a plant. **Customer types and end-markets.** As a future producer, Astral's end-market is the global gold bullion market. Gold has no meaningful customer concentration and sells at spot (A$-denominated for an Australian producer), possibly with hedging tied to project finance. The ultimate buyers are refiners (doré offtake) and, through them, investment, central-bank, jewellery and industrial demand. **Independent characterisation.** Astral is a well-funded, district-consolidating, bulk-tonnage, low-grade (about 1.0 g/t) open-pit gold developer. Its value depends on four things: (1) the A$ gold price, (2) converting a large, shallow, consistent ore body (Theia) into a bankable mine plan, (3) the approvals, heritage and third-party-rights path, and (4) financing about A$180–227M of pre-production capital without heavy dilution. Its strengths are location next to Tier-1 infrastructure, metallurgy (about 95% recovery at a coarse grind, per company presentations), large pit-constrained resources, and low discovery costs. Company presentations state discovery costs averaged A$17–19/oz for recent additions at Mandilla and Feysville. Its weaknesses are low head grade, which leaves margins exposed to cost inflation, and the repeated slippage of the DFS timetable (June 2026 → Q1 2027).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1985
South Perth, Australia
Anatara

Anatara Lifesciences Limited

Premium
Information Technology

| Field | Detail | |---|---| | Legal name | Anatara Lifesciences Ltd | | ABN | 41 145 239 872 | | Former names | None recorded (Market Index lists no former company names) | | Incorporation date | 15 July 2010 (IBISWorld enterprise profile, citing ASIC registration) | | Incorporation jurisdiction | Australia; for-profit company limited by shares, incorporated and domiciled in Australia (FY2026 financial report, Note 1) | | Registered office and principal place of business | c/- Perks, Level 8, 81 Flinders Street, Adelaide SA 5000, Australia (FY2026 corporate directory) | | Historical base | Brisbane, Queensland, at IPO and through roughly 2020. Registered office later moved to Adelaide. | | Exchange and ticker | Australian Securities Exchange (ASX: ANR); sole listing | | Other quoted securities | Listed options (7 cent exercise price, expiry 11 December 2025) lapsed unexercised on 11 December 2025. No other quoted securities remain. | | ISIN | AU000000ANR0 | | CUSIP | Not applicable; no US listing | | Fiscal year end | 30 June | | IPO | October 2014; raised A$7 million at A$0.50 per share. Listing date reported as 16 October 2014 by Pearler. The financialfilings.com summary states December 2014, which conflicts. | | Subsidiary | Sarantis Pty Ltd (Australia, 100%, dormant) | | Auditor | Grant Thornton Audit Pty Ltd, Adelaide; lead partner J L Humphrey | | Share registry | Computershare Investor Services Pty Ltd, Brisbane | | Solicitors | Thomson Geer, Brisbane | | Bankers | Commonwealth Bank of Australia | | Website | www.anataralifesciences.com | | Shares on issue | 315,950,765 ordinary shares at 30 June 2026. A small further issue followed in August 2026 from conversion of performance rights (Appendix 2A, 24 August 2026). | | Unquoted options | 10,500,000, with exercise prices of A$0.025 to A$0.10 (FY2026 directors' report) | | Performance rights | 496,702 at the date of the FY2026 report | | Last observed share price | About A$0.009 to A$0.010 (InvestSMART, August to September 2026). | | Market capitalisation | About A$2.8 million to A$3.2 million (315.95m shares × A$0.009 to A$0.010). StockAnalysis showed A$3.16m on 16 July 2026. | | Chief executive | No CEO. Dr David Brookes, Executive Chair, is the chief operating decision maker (FY2026 Note 5). | The entity profiled is the same listed company named in the request. There has been no name change, delisting, or change of listing venue. Anatara Lifesciences Ltd remains quoted on the ASX under code ANR. | Metric | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---| | Employee benefits expense excl. super (AUD k) | 687.6 | 695.6 | 660.2 | 551.7 | | Superannuation expense (AUD k) | 74.9 | 65.9 | 71.7 | 53.8 | | Total KMP remuneration (AUD k) | 786.9 | 716.3 | 685.0 | 444.4 | | Executive KMP count at year end | 3 | 3 | 2 | 1 | Anatara does not disclose headcount. The best available proxy is employee benefits expense plus the key management personnel (KMP) roster. At 30 June 2026 the only executive KMP was the Executive Chair. Chief Development Officer Simon Erskine resigned on 13 May 2026. FY2026 annual leave provisions were A$8,375 and long service leave A$599, which points to a workforce of perhaps one to three salaried staff, supported by contractors. This is an inference; the company does not state a figure. Anatara Lifesciences is an Adelaide-based, ASX-listed micro-cap biotech. It began as a bromelain-based animal health company built around Detach®, a non-antibiotic treatment for scour (diarrhoea) in piglets. Detach was licensed to Zoetis in 2018 and handed back in 2019. Anatara then repositioned toward human gastrointestinal health through GaRP (Gastrointestinal ReProgramming), a multi-component, multi-coated complementary medicine made from "Generally Regarded As Safe" (GRAS) ingredients. In April 2025, GaRP's Phase II trial in irritable bowel syndrome (IBS) missed its primary efficacy endpoint. The company has since run on austerity. It has explored an early-stage oral Anti-Obesity Project (compound "AOC"), aimed at limiting weight regain after patients stop GLP-1 drugs, while assessing corporate transactions. With cash of A$0.47 million at 30 June 2026, no product revenue, and a material-uncertainty going-concern opinion, Anatara is best characterised as a listed shell-like vehicle. Its value rests on residual GaRP IP, early anti-obesity data, A$14.2 million of carried-forward tax losses, and its ASX listing. --- ### Company's own description (FY2026 Annual Report) The FY2026 directors' report describes the group as an Australian listed entity that develops and commercialises innovative, evidence-based products for gastrointestinal health in areas of significant unmet need. It says the company is building a pipeline of human health products, with a particular focus on conditions involving the complexity of the gastrointestinal tract. The report states there was no significant change in principal activities during FY2026. The FY2025 annual report, released in October 2025, framed the strategy as using proprietary technology and strategic partnerships to build a pipeline of health products. ### Independent characterisation Anatara is a pre-revenue, single-segment development company. Its operating model is asset-light and virtual. It has no manufacturing, laboratories or clinical operations of its own. Pre-clinical work is outsourced to universities (most recently the University of Newcastle), clinical trials to contract sites, and formulation to contract manufacturers. Since the GaRP-IBS trial failed in April 2025, the business has three activities: 1. **Asset monetisation.** It is seeking to commercialise or license the GaRP IP and know-how. Manuscripts on the pre-clinical work and the trial have been submitted for publication. 2. **Option-value R&D.** It has run a modest (more than A$350,000) proof-of-concept programme on AOC. The programme was put on hold in the June 2026 quarter while other transactions were negotiated. 3. **Corporate development.** It is evaluating transactions in the junior healthcare sector. The last activity is now arguably the dominant value driver. It positions Anatara as a potential vehicle for a merger, asset injection or reverse takeover. ### Revenue model | Revenue type | Status (FY2026) | Commentary | |---|---|---| | Product sales | None | GaRP was never commercialised. Detach was approved in Australia historically, but no sales are recorded in FY2023 to FY2026. | | Services | None | Not applicable | | Subscription | None | Not applicable | | Licensing and royalties | None recognised | The Zoetis deal (2018–2019) produced up-front payments. Under its terms Anatara was to receive US$2.5m up-front, US$2m of which had been received by the time of Stockhead's coverage. No licensing income has been recorded in recent years. | | Government incentives | 100% of FY2026 other income | Refundable Australian R&D Tax Incentive (R&DTI): A$318,402 in FY2026 and A$969,456 in FY2025 | ### Value chain position | Stage | Anatara role | |---|---| | Discovery and formulation | In-house IP (multi-component, multi-coated GaRP formulation; AOC candidate selection) | | Pre-clinical | Outsourced (University of Newcastle for AOC; IBD mouse model work for GaRP) | | Clinical | Sponsor of GaRP-IBS Phase II run through contract sites (5 sites across 3 Australian capital cities in Q4 FY2024) | | Regulatory | Groundwork for listing on the Australian Register of Therapeutic Goods (TGA); regulatory framework work for the EU and US (FY2024 report) | | Manufacturing | Contract manufacturers; scale-up and packaging work started in FY2024; stability above 24 months demonstrated | | Commercialisation | Intended through out-licensing to pharma or consumer-health partners; no partner secured | ### Customer types and end-markets Anatara has no customers today. Its intended counterparties and end-markets are: **Global consumer health and pharma companies:** seeking evidence-based complementary medicines for gut health, IBS and the gut–brain axis (GaRP licensing). - **Weight-management and nutraceutical markets**, especially adjunct or maintenance products for people stopping GLP-1 receptor agonists (AOC). - **Animal health companies**, historically, for Detach, BONIFF (piglet dry-feed formulation) and ANR-pf (poultry in-water formulation). The FY2023 half-year report said interest in the bromelain animal portfolio would be pursued through consultancy agreements.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2010
Adelaide, Australia
Analytica

Analytica Limited

Premium
Information Technology

Analytica Limited was a Queensland micro-cap medical-device developer. For more than a decade it tried to commercialise the PeriCoach System, a connected pelvic-floor muscle trainer for women with stress urinary incontinence. PeriCoach combined an intravaginal sensor device, a smartphone app and a clinician web portal. The underlying exercise data was pooled in a cloud database the company described as the world's largest of its kind. The company also held a legacy infusion franchise: the AutoStart burette, later grouped with AutoFlush as the Enhanced Infusion System. PeriCoach obtained TGA, CE-mark and US FDA clearances, including US over-the-counter clearance in 2016. Despite this, revenue never scaled beyond a few hundred thousand dollars a year. By June 2022 the company had accumulated losses of about A$107.6 million. Its 2021 pivot to sovereign manufacturing in Maryborough and its China joint venture did not produce sustainable revenue. The company entered administration in June 2023 and was removed from the ASX in August 2023. --- **What the company did.** In its own corporate description, Analytica designed, developed and supplied Class I and Class II medical devices. Its stated aim was to build shareholder value by commercially developing viable, profitable devices. Third-party profiles (MarketBeat, Pearler) describe it as supplying medical devices in Australia, China and the Middle East. Those profiles name the PeriCoach System as the lead product and the AutoStart Burette Infusion System as the second product line. **Business model.** Analytica was a product-led medical-technology company. It generated revenue mainly from hardware sales of the PeriCoach device. Sales went through four channels: direct-to-consumer, clinician-referred sales, wholesale distributors (for example Current Technology, Inc. in the US from 2015), and from 2021 regional joint-venture and distribution partners in China and the Middle East. The app and web portal were bundled with the device. Accessible disclosures show no separately monetised subscription or SaaS revenue line. **Value-chain position.** Analytica was a design owner and regulatory sponsor. It outsourced manufacturing, first to a Sydney contract manufacturer from about 2014 and to offshore providers during the R&D and regulatory phases. It decided in 2021 to bring manufacturing in-house in Maryborough, citing better control of the supply chain and regulatory compliance. **Customer types and end-markets.** **Independent characterisation.** Analytica is a textbook example of a single-product ASX micro-cap medtech that won regulatory approval but never achieved commercial adoption. It obtained approvals in all three major Western regulatory systems (TGA, CE, FDA 510(k) and OTC) and built a defensible patent estate. However, it never found a partner with distribution scale. The company had said publicly in 2016 that it was looking for a major multinational partner, and no such deal was ever announced. Repeated reliance on loans from the chairman, small placements and government grants left the company structurally undercapitalised. This is consistent with management's own admission, reported by Biotech Daily in 2017, that limited capital had been a long-running difficulty.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1985
Brisbane, Australia
Ampol

Ampol Limited

Premium
Information Technology

Ampol is Australia's largest transport-fuels company and its only integrated downstream fuels supplier. Its chain spans crude and product sourcing through an independent Singapore and Houston trading and shipping arm, refining at Lytton (Brisbane), import terminals, pipelines and depots, wholesale supply to commercial, mining, aviation and defence customers, and Australia's largest branded convenience-retail network. In New Zealand it operates through Z Energy, the market-leading fuels distributor acquired in 2022. Morningstar estimates Ampol holds about 35% of Australian transport-fuel sales. In June 2026 Ampol completed the A$1.1 billion acquisition of EG Australia, which takes its company-controlled retail estate above 1,000 sites. The business is cyclical at the refining margin and structurally stable in fuel distribution and convenience retail. It is also strategically important to national fuel security, a role that was amplified when the 2026 Middle East conflict disrupted Asian product supply. The group's medium-term challenge is to harvest fuels cash flows while building EV charging, lower-carbon fuels and non-fuel retail earnings. --- ### What Ampol does Ampol purchases, refines, imports, stores, distributes and markets petroleum products, mainly petrol, diesel, jet fuel, LPG, lubricants and specialty products, across Australia and New Zealand. Its trading entities in Singapore and the United States supply third parties across the Asia-Pacific. It also owns and operates convenience retail stores, an unstaffed discount fuel format (U-GO), and a growing public EV fast-charging network (AmpCharge). **Company self-description (paraphrased from the 2025 Integrated Report and the results releases):** Ampol describes itself as a leading independent fuels and convenience company. It says it is underpinned by an integrated supply chain made up of domestic refining, independent trading and shipping, and market-leading infrastructure. It states its role as safely and reliably supplying the energy needs of customers in Australia and New Zealand while transitioning in line with customer demand. Its FY2025 report was the first under the mandatory Australian Sustainability Reporting Standard AASB S2. ### Business model and revenue model | Revenue stream | Nature | Approximate character | |---|---|---| | Wholesale fuel sales (F&I Australia) | Product sales under term supply contracts and spot to mining, transport, aviation, marine, agriculture, government and defence, resellers and distributors, and supply to independent and franchised retail networks (historically including EG Australia under a 15-year supply agreement) | Product sales; earnings driven by volume × unit margin | | Refining (Lytton) | Crude processed into products and transferred internally or sold | Product sales; earnings driven by Lytton Refiner Margin (LRM), throughput and reliability, plus government Fuel Security Services Payment (FSSP) support | | Trading & shipping (F&I International) | Cargo trading, freight, third-party sales from Singapore and Houston; 20% SEAOIL Philippines | Product sales plus trading margin | | Convenience Retail (Australia) | Retail fuel at company-operated sites (Ampol, U-GO and, from 1 July 2026, EG sites) plus shop sales (food, beverages, convenience goods) | Product retail; shop gross margin 40.1% in 1H 2026 (post waste and shrink) | | New Zealand (Z Energy) | Retail (Z and Caltex-branded sites in NZ), commercial, aviation and marine fuel sales | Product sales | | Energy Solutions | AmpCharge EV charging, lower-carbon fuels development, energy services | Service and usage fees; currently loss-making | | Brand licensing / fuel cards | Brand licences to dealer and EG networks, fuel cards | Licensing and service fees (small) | Product sales account for the overwhelming majority of reported revenue (FY2025 revenue about A$31.0 billion). Service, subscription and licensing revenue is immaterial and not separately disclosed. Earnings, however, are much more diversified than revenue suggests. After the EG deal, Ampol stated that fuel and convenience plus fuel-marketing businesses across Australia and New Zealand would make up about 85% of group earnings (company release, August 2025). ### Value-chain position Ampol sits in the downstream oil value chain. It covers: **Supply and trading:** sourcing crude for Lytton and refined products for import. **Refining:** Lytton, one of two remaining Australian refineries; the other is Viva Energy's Geelong refinery. **Infrastructure:** per a 2025 government submission, 14 terminals, six major pipelines, 53 wet depots and about 1,800 branded retail sites in Australia. **Marketing and retail:** Ampol has no upstream exposure. Kurnell (Sydney) ceased refining in 2014 and has operated since then as Australia's largest import terminal. ### Customer types and end-markets | Customer group | Examples / notes | |---|---| | Retail motorists | About 1,766 Ampol-branded sites as at 30 June 2024, including 633 company-operated (1H 2024 report); 622 company-operated incl. 46 U-GO at 31 December 2025 (FY2025 release); EG Australia's ~500 sites added 30 June 2026 | | Mining and resources | Diesel supply, often under long-term contracts | | Transport and logistics | Diesel, AdBlue, fuel cards | | Aviation | Jet fuel (Australia and NZ) | | Marine | Marine fuels, especially NZ (Z Energy) | | Agriculture | Diesel distribution via depots and resellers | | Government and defence | Fuel supply; Ampol is a strategic supplier under fuel-security arrangements | | Resellers / independent networks | Branded dealers, distributors, independent chains | | International third parties | Trading counterparties in Asia; SEAOIL (Philippines) | ### Independent characterisation Ampol is best understood as three businesses with very different economics wrapped in one supply chain. 1. **The "toll-road" fuels distribution and infrastructure business.** This covers F&I Australia ex-Lytton plus New Zealand. It produced about A$505 million of combined RCOP EBIT in FY2025 (F&I Australia ex-Lytton A$272.1 million plus NZ A$233.9 million). Its earnings are stable, it scales with volume, and its infrastructure position is hard to replicate. 2. **A high-volatility merchant refinery (Lytton) and trading arm.** Earnings swing from losses (about −A$42 million RCOP EBIT in FY2024 per secondary reporting) to windfalls (A$533.4 million in 1H 2026 alone). This swing is driven by Singapore product cracks, crude freight and FX. 3. **A growing convenience retail business.** It produced A$373.7 million RCOP EBIT in FY2025, which will be materially enlarged by EG Australia. Valuation and credit outcomes depend chiefly on the mix between the stable first and third businesses and the cyclical second one. The EG acquisition is a deliberate move to tilt that mix toward retail.

Revenue$20.0B
EmployeesN/A
Market CapN/A
Founded1900
Alexandria, Australia
Amplia

Amplia Therapeutics Limited

Premium
Information Technology

Amplia Therapeutics is a Melbourne-based, single-asset-centric oncology developer. Its lead asset is narmafotinib (AMP945), a highly selective oral inhibitor of focal adhesion kinase (FAK). FAK drives fibrotic stroma, immune suppression and drug-resistance signalling in solid tumours. Narmafotinib holds US FDA Orphan Drug and Fast Track designations in pancreatic cancer. In the single-arm Phase 1b/2a ACCENT trial it was combined with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer. The combination produced a centrally reviewed objective response rate of 35.9%, a 7.8% complete response rate, median PFS of 7.7 months and median OS of 11.1 months, each numerically above the historical MPACT chemotherapy benchmark. The strategy is to make narmafotinib a "combination backbone": a registration path in pancreatic cancer (ACCENT Mini, then a Phase 2b/3), an ovarian cancer study with ANZGOG, and a KRAS-inhibitor combination in NSCLC with Eli Lilly. The company is funded by equity and the R&D Tax Incentive. It has no revenue and is roughly six quarters from needing new capital at current burn. --- ### Company's own description (FY2026 Annual Report, Directors' Report) The FY2026 directors' report gives the principal activity as developing two FAK-inhibiting drug candidates, narmafotinib (AMP945) and AMP886. According to the report, both compounds have strong potency and selectivity, good pharmacokinetics and drug-like properties, preclinical efficacy, and chemistry suited to manufacturing scale-up and long-term stability. The company is pursuing them across oncology (notably pancreatic cancer) and chronic fibrotic disease. The boilerplate "About Amplia" text calls the company an Australian pharmaceutical business advancing a pipeline of FAK inhibitors for cancer and fibrosis, with a focus on fibrotic cancers such as pancreatic and ovarian cancer. ### Independent characterisation | Revenue component (FY2026, AUD) | Amount | % of total | |---|---|---| | R&D Tax Incentive (refundable offset) | 4,778,235 | 87.0% | | Interest income | 699,097 | 12.7% | | Government grants | 12,000 | 0.2% | | Other income | 1,000 | 0.0% | | Total revenue and other income | 5,490,332 | 100% | | Market | Size claimed (USD) | Basis | |---|---|---| | Pancreatic cancer | 2.5 billion | 2025, 7 major markets | | Ovarian cancer | 3.9 billion | 2025, 7 major markets | | Lung cancer | 32 billion | global | | Colorectal cancer | 19 billion | global | Amplia is a virtual, outsourced, clinical-stage small-molecule developer. Its value chain position is in-licensed discovery-stage IP taken through clinical development, with the aim of partnering or out-licensing before Phase 3 or commercialisation. The model is capital-light: **Discovery origin:** the Cancer Therapeutics CRC (CTx), Melbourne. Intellectual property is in-licensed from Cancer Research Technology Ltd (CRT, now Cancer Research Horizons) under a March 2018 licence. **Manufacturing:** outsourced to a contract development and manufacturing organisation. Laurus (India) is named for API manufacture. **Clinical execution:** outsourced to CROs and hospital sites in Australia, South Korea and the US, plus investigator-initiated trials sponsored by cooperative groups (ANZGOG). **Partnering:** non-exclusive clinical supply collaborations with large pharma (Eli Lilly, August 2026). These are not licensing deals. **Revenue model.** There is currently no product, service, subscription or licensing revenue. The mix is: Source: FY2026 consolidated statement of profit or loss. **Prospective revenue model.** The intended route to value is one or more of the following: - out-licensing or co-development of narmafotinib with a pharma partner, earning upfront, milestone and royalty payments; - acquisition of the company; - less likely given its scale, eventual direct commercialisation in orphan pancreatic cancer. Royalty obligations upstream reduce net economics. Milestones are owed to CRT and the Garvan Institute, and a legacy 3.25% royalty is owed to the original MIS416 vendors on any MIS416 revenues (that legacy asset is dormant). **Customer types and end-markets (prospective).** The ultimate payers would be oncology prescribers and health systems. The commercial counterparties would be large and mid-cap pharma companies. End-markets per the company's September 2026 presentation, citing Clarivate / Nature Reviews Drug Discovery 2026 and Fortune Business Insights:

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2000
Melbourne, Australia

Page 229 of 482

1…228229230…482

Page 229 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo